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ABSTRACT   
To update the melanoma staging system of the previous (Seventh) edition of the American Joint 
Committee on Cancer (AJCC) Cancer Staging Manual published in 2009, a large database was 
assembled comprising >46,000 patients from 10 centers worldwide with Stages I, II, and III melanoma 
diagnosed since 1998.  Based on analyses of this new database, the existing Seventh Edition AJCC 
Stage IV database, and contemporary clinical trial data, the AJCC Melanoma Expert Panel introduced 
several important changes to the TNM classification and stage grouping criteria.  These were 
incorporated into the Eighth Edition AJCC Cancer Staging Manual. Key changes include:  (1) tumor 
thickness measurements to be recorded to the nearest 0.1 mm, not the nearest 0.01 mm; (2) definitions 
of T1a and T1b revised (T1a, <0.8 mm without ulceration; T1b, 0.8-1.0 mm with or without ulceration, or 
<0.8 mm with ulceration), with mitotic rate no longer a T category criterion; (3) pathological (but not 
clinical) Stage IA revised to include T1b N0 M0 (formerly pathological Stage IB); (4) N category 
descriptors “microscopic” and “macroscopic” for regional node metastasis redefined as “clinically occult” 
and “clinically apparent”; (5) prognostic Stage III groupings based on N category criteria and T category 
criteria (i.e., primary tumor thickness and ulceration) and increased from three to four subgroups (Stage 
IIIA-IIID); (6) definitions of N subcategories revised, with presence of microsatellites, satellites or in-
transit metastases now ategorized as N1c, N2c or N3c based on number of tumor-involved regional 
lymph nodes, if any; (7) descriptors added to each M1 subcategory designation for LDH level (LDH 
elevation no longer automatically upstages to M1c); (8) a new M1d designation for metastases involving 
the central nervous system.  This evidence-based revision of the AJCC melanoma staging system will 
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guide patient treatment, provide better prognostic estimates, and further refine eligibility and stratification 
of patients entering clinical trials.    
 
 
Keywords:  American Joint Committee on Cancer (AJCC), melanoma, database, TNM classification, 
staging, stage groupings, pathology, tumor thickness, ulceration, mitotic rate, regional lymph nodes, 
sentinel lymph node, visceral metastasis, brain metastasis, prognosis, survival  
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INTRODUCTION 
To improve the outcomes of patients with cutaneous melanoma, treatment based on accurate 
staging and patient stratification into clinically-relevant stage groups is fundamental.  Not only does 
staging inform prognostic assessment and clinical decision making, but it also facilitates centralized 
cancer registry reporting and the design, conduct and analysis of clinical trials.  
Since the early 1990s, a major advance in the management of patients with cutaneous melanoma 
involves the technique of lymphatic mapping and sentinel lymph node (SLN) biopsy;1 this is now routinely 
employed as a staging procedure2 for patients with T1b, T2, T3 and T4 (Eighth Edition) primary 
cutaneous melanomas and clinically negative regional lymph nodes in most melanoma treatment centers 
throughout the world.3  The frequency of SLN metastasis increases with increasing tumor thickness and 
other adverse clinicopathological prognostic factors.3-5  Clinical imaging technologies have also 
advanced, having become more sophisticated and more widely available, facilitating the detection of 
distant metastatic disease when it is of low volume and asymptomatic.  
More recently, based upon improved knowledge of both the molecular pathogenesis of melanoma 
and cancer immunology, there has been a revolution in the treatment of patients with advanced stage 
and unresectable melanoma.6-21  This has already resulted in major improvements in patient outcomes.3  
Two major new classes of effective systemic therapeutic agents are now in widespread clinical use:  
immunotherapies (e.g., checkpoint inhibitors against cytotoxic T lymphocyte antigen 4 (CTLA-4) and/or 
programmed death 1 (PD-1)) that enhance the natural host antitumor immune response, and molecularly 
targeted antitumor therapies (e.g., BRAF inhibitors alone or in combination with MEK inhibitors for the 
approximately 40 to 50% of patients with BRAFV600 mutant melanoma).22  Moreover, adjuvant therapy 
with anti-CTLA-4 significantly improves relapse-free survival and overall survival in stage III melanoma 
patients.23, 24  It is against this background that the American Joint Committee on Cancer (AJCC) 
appointed a Melanoma Expert Panel to undertake the task of revising the cutaneous melanoma staging 
system for the Eighth Edition of the AJCC Cancer Staging Manual. 
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 The Seventh Edition AJCC melanoma staging system (hereafter referred to as the Seventh 
Edition) has been widely adopted since its publication in 2009 and implementation in 2010.2, 25  For the 
Eighth Edition AJCC melanoma staging system (hereafter referred to as the Eighth Edition), a 
contemporary international database was assembled to provide an evidence-based rationale for 
revisions to the cutaneous melanoma staging system that would have more current applicability.3  The 
objective was to analyze detailed multi-institutional clinicopathological data collected in a standardized 
fashion to empirically establish T, N, and M categories and stage groupings for the Eighth Edition.  We 
report here the results of analyses using this large melanoma database, supplemented by analyses from 
the Seventh Edition AJCC Stage IV database and by contemporary clinical trial data.  These provided 
the evidence base for revisions of the Eighth Edition as well as the UICC Eighth Edition TNM 
Classification of Malignant Tumours.26  The revised T, N, and M categories and stage groupings are 
presented below.  To ensure that the necessary infrastructure is in place across the cancer care 
community, the Eighth Edition, originally published in October 2016, will not be formally implemented in 
the U.S. until January 1, 2018.27 
 
DATABASE and METHODS 
To assist the Eighth Edition Melanoma Expert Panel in its review of T and N categories and Stage 
I to III subgroupings, a protocol-based International Melanoma Database and Discovery Platform 
(IMDDP) was created at The University of Texas MD Anderson Cancer Center (MD Anderson), Houston, 
TX, USA.  This protocol was approved by the MD Anderson Institutional Review Board (IRB) and formal 
data use agreements were implemented across all participating institutions, each also having obtained 
approval from their own IRB.  This overall approach built upon collaborative efforts of the previous AJCC 
Melanoma Task Forces (renamed the AJCC Melanoma Expert Panel for the Eighth Edition) and an 
expanded network of national and international academic melanoma clinician–investigators representing 
institutions, cooperative groups, and tumor registries.  The database included de-identified patient 
records from 10 institutions in the United States, Europe and Australia, with well-annotated 
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clinicopathological and follow-up data for patients with Stages I to III melanoma at initial diagnosis, 
treated since 1998.  Importantly, the database reflected a contemporary clinical practice era during which 
the use of lymphatic mapping and SLN biopsy was well established in nearly all academic medical 
centers worldwide for patients considered at significant risk for occult regional node metastasis.  Patients 
treated in the pre-SLN era (i.e., pre-1990s) as well as the early SLN era (early through mid-1990s) were 
deliberately omitted.  During this latter period, SLN biopsy surgical techniques had evolved and matured 
(with development and implementation of a dual-modality intraoperative approach using blue dye and a 
radiotracer with gamma probe detection) and pathological assessment of the SLN (with widespread 
implementation of “enhanced” pathological assessment using step or serial sectioning and 
immunohistochemistry).1, 2, 28-32 
 For the analyses undertaken for the Eighth Edition, the database platform included the records of 
more than 46,000 melanoma patients (Supplementary Table 1), of whom 43,792 qualified for analysis.  
Only data from patients for whom relevant covariates (Supplementary Table 2) were known were 
included in each analysis.  
 Given the unprecedented changes in the still rapidly evolving landscape of the management of 
patients with Stage IV melanoma, the Melanoma Expert Panel concluded that it was premature to 
embark on a broad-based analytic initiative involving data from Stage IV patients treated during the past 
8 years.  Instead, the legacy 7th Edition AJCC Stage IV international melanoma database containing 
details of approximately 10,000 patients who presented with or developed Stage IV disease was used as 
the primary data source for the 8th Edition, supplemented by published contemporary clinical trial data.6-21 
 
Statistical Analyses 
Melanoma-specific survival (MSS) was calculated from the date of initial melanoma diagnosis.  MSS 
curves were computed using the Kaplan-Meier method.  Multivariable analyses were conducted using 
Cox proportional hazards regression models and recursive partitioning analysis (RPA).  Analyses were 
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performed using S+ (Windows version 8.2, TIBCO, software, Inc.).  RPA was performed using the S+ 
“tree” libraries on the MSS null martingale residuals.  
 
MAJOR CHANGES 
Table 1 summarizes the major changes introduced for the T, N, and M categories and stage groupings in 
the Eighth Edition.  The rationale for these changes is described below. 
The T Category  
Breslow Tumor Thickness 
In prior editions of the AJCC Cancer Staging Manual,2, 25 it was implied (but not explicitly stated) 
that primary melanoma tumor thickness should be recorded to the nearest 0.01 mm.  This has been 
clarified in the Eighth Edition.  Based on consensus recommendations by the International Collaboration 
on Cancer Reporting33 and the International Melanoma Pathology Study Group, already widely adopted 
in the pathology community,34 thickness measurements should be recorded to the nearest 0.1 mm, not 
the nearest 0.01 mm, because of the impracticality and imprecision of measurements,34 particularly for 
tumors >1 mm thick, and the reality that tumor thickness may vary by 0.1 mm or more between different 
histological tissue sections cut from the same paraffin tissue block of the tumor.35  Tumors ≤1mm thick 
may initially be measured to the nearest 0.01 mm, but should be rounded up or down to be recorded to 
the precision of a single digit after the decimal (i.e., to the nearest 0.1 mm).  The convention for rounding 
decimal values is to round down those ending in 1 to 4 and to round up those ending in 5 to 9. For 
example, a melanoma measuring 0.75 mm in thickness would be recorded as 0.8 mm in thickness (i.e., 
T1b).  Tumors measuring 0.95 mm through 1.04 mm would be rounded to 1.0 mm (i.e., T1b).  Primary 
tumor thickness should be measured using an ocular micrometer that has been calibrated to the 
magnification of the microscope used for the measurement.  Microsatellites should not be included in the 
measurement of tumor thickness. Additional specific recommendations for the measurement of tumor 
thickness in particular clinical circumstances have been previously documented33 and will be further 
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 12
detailed in a planned separate publication on pathological aspects of melanoma staging from the 
International Melanoma Pathology Study Group. 
 In the Eighth Edition, the T-category thresholds of melanoma thickness continue to be defined at 
1, 2, and 4 mm (Table 2).36  However, the T categories have been revised to promote consistency, with 
the recommendation that thickness be rounded to the nearest 0.1 mm, as described above.  Using these 
rounding conventions, T2 melanomas include patients with melanomas with a tumor thickness of 1.05 
mm to 2.04 mm; T2 is now presented as >1.0–2.0 mm, compared to 1.01–2.0 mm in the Seventh 
Edition.37, 38   
Several previously published reports have indicated that survival among patients with T1 
melanomas is related to tumor thickness, with a possible clinically important “breakpoint” in the region of 
0.7 mm-0.8 mm.39-42  These observations were explored in the IMDDP database by seeking to identify a 
subgroup of patients with exceptionally good outcome compared to even the most favorable subcategory 
(T1a) in the Seventh Edition,25 and hence in whom SLN biopsy would generally not be indicated.  In the 
T1 cohort, the impact on outcome of a 0.8 mm tumor thickness threshold was evaluated, as well as 
mitotic rate (as a dichotomous variable, <1 mitosis per mm2 vs. ≥1 mitosis per mm2) and ulceration.  In a 
multivariable analysis of factors predicting MSS (including tumor thickness, ulceration, and mitotic rate) 
among 7,568 T1 N0 patients, tumor thickness ≥0.8 mm had a hazard ratio (HR) of 1.7 vs. <0.8 mm (p = 
0.057), ulceration had a HR of 2.6 vs. non-ulcerated (p = 0.035), and mitotic rate ≥1/mm2 had a HR of 
0.85 vs. mitotic rate <1/mm2 (p = 0.57).  Based on these analyses of patients with T1 melanomas, tumor 
thickness (when dichotomized as <0.8 mm and 0.8-1.0 mm) and ulceration were stronger predictors of 
MSS than mitotic rate.  Accordingly, since mitotic rate was not statistically significant in the model, T1 
subcategory definitions have been revised:  T1a is now defined as nonulcerated melanomas <0.8 mm in 
thickness and T1b as melanomas 0.8-1.0 mm in thickness regardless of ulceration status, plus ulcerated 
melanomas <0.8 mm in thickness (Table 2).  The Eighth Edition Melanoma Expert Panel also noted that 
the sub-categorization of T1 melanomas at a 0.8 mm threshold has clinical relevance, particularly for the 
role of SLN biopsy in patients with T1 melanomas.  Overall, SLN metastases are very infrequent (<5%) 
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in melanomas <0.8 mm but occur in approximately 5%-12% of patients with primary melanomas 0.8-1.0 
mm,43-46 and consensus guidelines have recommended that SLN biopsy be considered in this latter 
group of patients, particularly when other adverse prognostic parameters are also present.47-49 
 As in the Seventh Edition, patients with primary melanoma and no evidence of regional or distant 
metastasis are stratified into eight T subcategories (T1a through T4b).  MSS stratified by T subcategory 
for 23,001 patients with complete covariate data is shown in Figure 1.  For these survival curves, 
patients with T1 melanomas were included if they had clinical or pathological T1 N0 melanomas, but 
patients with T2-T4 melanomas were included only if pN0 (i.e., no tumor-containing SLNs and no 
evidence of microsatellites, satellites, or in-transit metastases at diagnosis or following initial treatment).   
Overall, this approach aligns with the AJCC Principles of Cancer Staging (see chapter 1 of the Eighth 
Edition AJCC Cancer Staging Manual).56  An implication of this approach is that patients with T2-T4 
melanomas who do not undergo SLN biopsy cannot be pathologically staged.  Nonetheless, the 
Melanoma Expert Panel acknowledges that not all patients with T2-T4 undergo SLN biopsy and 
improved clinical prognostic models and tools (e.g., clinical calculators, etc.) may be developed to 
improve prognostic assessment among this cohort of patients in the future. 
In the Eighth Edition, five- and ten-year MSS ranged from 99% and 98%, respectively, for patients 
with T1a N0 melanomas (i.e., primary tumor thickness <0.8 mm, non-ulcerated), to 82% and 75%, 
respectively, for patients with T4b N0 melanomas (i.e., primary tumor thickness >4.0 mm, ulcerated). 
MSS for all T subcategories were notably higher than those reported in the Seventh Edition, in which 10-
year MSS was 93% and 39% for T1a N0 and T4b N0 melanomas, respectively.50  The higher survival of 
patients in the more contemporary patient cohort examined in this Eighth Edition effort is likely a 
consequence of the widespread use of SLN biopsy, the requirement for SLN biopsy for patients with T2-
T4 primary melanoma to be included in AJCC staging, and, to a lesser extent, newer imaging 
technologies that improve detection of clinically occult metastatic disease, thereby defining more 
homogenous groups of patients and achieving more accurate staging.36 38  Some patients, who in the 
past would have been classified as clinically node negative (cN0), would be expected to harbor clinically 
Comment [TG6]: I never thought about this 
point before, but in reading this sentence, I’m 
curious whether this approach has been used 
for other sites as well. If so, it might be worth 
noting that this is a consistent practice for 
AJCC. 
Comment [TG7]: Some CA readers may not 
understand this without a more tangible 
explanation, so it might be useful to explain 
that some patients who in the past would have 
been classified as N0 now have a positive 
SLNB and are classified as N1. 
Page 13 of 115 CA: A Cancer Journal for Clinicians
This article is protected by copyright. All rights reserved.
A
cc
ep
te
d 
A
rt
ic
le
 
 14
occult nodal metastasis identified on the basis of a positive SLN biopsy and are classified as pN1, pN2, 
etc., according to the overall number of tumor-involved lymph nodes.  In one study, for example, the risk 
of harboring a positive SLN ranged from 11% in patients with T1a melanoma to 53% in patients with T4b 
melanoma.51  Overall, the presence of an ulcerated primary was generally associated with a MSS 
approximately similar to that of a patient with a nonulcerated primary tumor in the next highest tumor 
thickness category.   
Other T category definitions have been clarified in the Eighth Edition.  Patients with melanoma in 
situ are properly categorized as Tis (not T0, which is reserved for an unknown or completely regressed 
primary site).  Since tumor thickness can only be evaluated accurately in histological sections cut 
perpendicular to the epidermal surface, the T category should be recorded as TX if the thickness cannot 
be assessed (e.g., in curettage specimens when no tissue fragment shows a complete section of the 
tumor cut perpendicular to the surface).  In some instances, if the tissue has been misembedded, melting 
the paraffin block and re-embedding the tissue may enable perpendicular sections to be obtained.  If 
there is evidence of regression of part of an invasive melanoma, the thickness should be measured in 
the usual way to the deepest identifiable viable tumor cell, and the tumor should be assigned to the 
appropriate T category.  Partially regressed melanoma should not be designated TX or T0.  T0 should be 
used if there is no evidence of a primary tumor (e.g., in a patient who presents with nodal or visceral 
metastasis and no known primary tumor), or if a melanoma has regressed completely.  If the invasive 
component of the melanoma has regressed but overlying in situ melanoma remains, the tumor should be 
designated Tis. 
 
Ulceration 
Primary tumor ulceration is another T category criterion.  In the Eighth Edition, as in the Seventh 
Edition,38 the absence or presence of ulceration is designated “a” or “b”, respectively, in each T 
subcategory (e.g., T2a and T2b correspond to non-ulcerated and ulcerated T2 melanomas, 
respectively)(Table 2).  Ulceration is defined as the full thickness absence of an intact epidermis above 
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any portion of the primary tumor with associated host reaction (characterized by a fibrinous and acute 
inflammatory exudate) above the primary tumor, based on histopathological examination.  If there is no 
host reaction, this likely represents artefactual loss of an intact epidermis overlying the primary 
melanoma and the melanoma should not be recorded as ulcerated, since this may have resulted from 
sectioning artifact caused by the tissue sectioning techniques used in the laboratory.  Epidermal loss 
caused by a prior biopsy should not be recorded as ulceration for staging purposes.  If ulceration is 
present in either an initial partial biopsy or a re-excision specimen of a primary melanoma, then the tumor 
should be recorded as ulcerated for staging purposes.  While the presence of “squared off” edges of a 
scar can provide a clue to the presence of iatrogenic (prior biopsy related) ulceration, at times it may be 
difficult or impossible to distinguish between iatrogenic and non-iatrogenic causes of ulceration on the 
basis of histopathologic assessment alone, and correlation with the clinical history is essential.52  If doubt 
remains as to whether ulceration is traumatic or iatrogenic in origin, the tumor should be staged as an 
ulcerated primary tumor. 
Ulceration is an adverse prognostic factor;25, 36, 37, 41, 53 the presence of an ulcerated primary was 
generally associated with a MSS similar to that of a patient with a nonulcerated primary in the next 
highest tumor thickness category (Figure 1).  For example, the 5- and 10-year MSS for patients with T2b 
pN0 and T3a pN0 primary cutaneous melanomas are 93% and 88%, and 94% and 88%, respectively. 
 
Mitotic rate 
Mitotic rate, defined as the number of mitoses per square millimeter in the invasive portion of the 
tumor using the “hot spot” method,3,36 (i.e., count beginning in a region where mitoses are more frequent 
and continue in immediately adjacent non-overlapping high power fields), was a T1 category criterion in 
the Seventh Edition;37,38 it was included as a dichotomous variable defined as <1/mm2 versus ≥1/mm2.  In 
the Eighth Edition, mitotic rate was not included as a T1 staging criterion (based on the T1 analysis 
described in the tumor thickness section above).  Nevertheless, among patients with clinically node 
negative (cN0) primary melanoma in the Eighth Edition AJCC melanoma database, increasing mitotic 
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rate was significantly associated with decreasing MSS in univariate analysis (Figure 2).  For example, in 
a univariate analysis of MSS for patients with T1-4 pN0 melanoma according to mitotic rate 
(mitoses/mm2) when categorized as <1, 1-3, 3-10, >10, the 5- and 10-year MSS ranged from 99% and 
97% in patients whose primary tumor had <1 mitosis/mm2 to 84% and 77% in patients whose primary 
tumors had ≥11 mitoses/mm2, respectively (p < 0.0001, log rank test).  As supported by this univariate 
analysis and previous reports,54, 55 mitotic rate is likely an important prognostic determinant when 
evaluated using its dynamic range across melanomas of all tumor thickness categories.  Therefore, the 
AJCC Melanoma Expert Panel strongly recommends that mitotic rate be assessed and recorded for all 
primary melanomas,3, 36 even though it is not used for T1 staging in the Eighth Edition.  Mitotic rate will 
likely be an important parameter for inclusion in the future development of prognostic models applicable 
to individual patients.  While not included in the T1 subcategory criteria, mitotic activity in T1 melanomas 
has been previously shown to be associated with increased risk of sentinel lymph node metastasis.43, 46, 
56, 57 
 
The N category 
The N category documents metastatic disease both in regional lymph nodes and in non-nodal 
loco-regional sites (i.e., microsatellites, satellites and in-transit metastases).  For the Eighth Edition, the 
Melanoma Expert Panel sought to add further granularity throughout the N category by providing clarity 
of definitions. 
Regional Lymph Node Metastasis  
In the Eighth Edition, N category criteria continue to include both extent of regional node tumor 
involvement and number of tumor-involved regional nodes.  “Clinically occult” nodal metastasis describes 
patients with microscopically identified regional node metastasis detected by SLN biopsy and without 
clinical or radiographic evidence of regional node metastasis (termed “microscopic” nodal metastasis in 
the Seventh Edition).  In contrast, “clinically detected” nodal metastasis describes patients with regional 
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node metastasis identifi d by clinical, radiographic or ultrasound examination (termed “macroscopic” 
nodal metastasis in the Seventh Edition) and usually (but not necessarily) confirmed by biopsy.58  
Clinically occult (N1a, N2a, N3a) and clinically detected (N1b, N2b, N3b) N subcategories define 
patients with regional node disease based on extent of regional node involvement and number of tumor-
involved regional nodes among patients without satellites, microsatellites, or in-transit metastases (Table 
3).  If at least one node is clinically detected, and there are additional involved nodes detected only on 
microscopic examination, the total number of involved nodes (i.e., both those clinically detected and 
those identified only on microscopic examination of a complete lymphadenectomy specimen) should be 
recorded for N subcategory based on the total number of tumor-involved regional nodes.  If 
microsatellites, satellites or in-transit metastases are present, patients are assigned to an N “c” 
subcategory according to the number of tumor-involved regional nodes, regardless of whether clinically 
occult or clinically detected:  N1c, N2c or N3c if 0, 1 or ≥2 regional nodes contain tumor, respectively 
(Table 3). 
As noted in the Seventh Edition, there is no unequivocal evidence that there is a lower threshold 
for the size of a clinically occult melanoma regional node tumor deposit that defines node-positive 
disease for staging purposes.  Thus, a lymph node in which any metastatic tumor cells have been 
identified, irrespective of how small the tumor deposit or whether it has been identified on H&E-stained or 
immunostained sections, should be designated as a tumor-involved lymph node.  In the Eighth Edition, it 
has been clarified that if melanoma cells are found in a lymphatic channel within or immediately adjacent 
to a lymph node, that node is regarded as tumor-involved for staging purposes. 
 In the Eighth Edition, the term “gross extranodal extension” is no longer used as an N category 
criterion, but the presence of matted nodes (defined as two or more nodes adherent to one another 
through involvement by metastatic disease, identified at the time the specimen is examined 
macroscopically in the pathology laboratory) is retained as an N3 criterion.  Even though it is not formally 
included as an Eighth Edition N category criterion, the definition of extranodal extension (ENE, also 
termed extranodal spread or extracapsular extension) has been clarified.  In the Eighth Edition, ENE is 
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defined as the presence of a nodal metastasis extending through the lymph node capsule and into 
adjacent tissue, which may be apparent macroscopically but must be confirmed microscopically.  It is 
recommended that this factor be recorded, as it may be useful for future analyses.59 
Patients with clinically occult regional node disease have been shown in several large series to 
have better survival than patients with clinically evident disease.50, 60, 61  This was also evident in the 
AJCC MSS curves according to N category and N subcategory, shown in Figure 3.  Overall, consistent 
with our observations in the Seventh Edition,25, 37, 62 there is marked heterogeneity in prognosis among 
patients with Stage III regional node disease by N-category designation.  
Non-nodal Locoregional Metastases (Microsatellite, Satellite and In-transit Metastases) 
The presence or absence of microsatellite, satellite or in-transit metastases, regardless of the 
number of such lesions, are components of the N category in the Eighth Edition (Table 3).  They are all 
thought to represent metastases that are a consequence of intralymphatic or possibly angiotropic tumor 
spread.  Satellite metastases have classically and somewhat arbitrarily been defined as clinically evident 
cutaneous and/or subcutaneous metastases occurring within 2 cm of the primary melanoma.50, 63  
Microsatellites have classically been defined as microscopic cutaneous and/or subcutaneous metastases 
found adjacent or deep to a primary melanoma on pathological examination (see discussion below).  In-
transit metastases have classically and somewhat arbitrarily been defined as clinically evident cutaneous 
and/or subcutaneous metastases identified at a distance more than 2 cm from the primary melanoma in 
the region between the primary and the first echelon of regional lymph nodes.63  Beginning with the Sixth 
Edition AJCC melanoma staging system, satellite and in-transit metastases were merged into a single 
staging entity reflective of intralymphatic regional metastases.63  Occasionally, satellite or in-transit 
metastases may occur distal to the primary site.  An N “c” subcategory has been added into each of the 
N1, N2 and N3 categories (i.e. N1c, N2c, N3c)(Table 3) in the Eighth Edition to incorporate 
contemporary knowledge of the prognostic importance of non-nodal locoregional metastases, and to 
simplify the application of staging rules for patients with them.  Microsatellites, satellites and in-transit 
metastases have been shown to portend a relatively poor prognosis.64-70  In univariate analysis of the 
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Eighth Edition database that included patients with or without synchronous regional node involvement, 
there was no significant difference in survival outcome for these anatomically defined entities (Figure 4); 
hence, they were grouped together for staging purposes (Table 3).  Planned IMDDP multivariable 
analyses will further explore the prognostic impact of non-nodal regional disease on MSS. 
In the Seventh Edition, a microsatellite was defined as “any tumor nest >0.05 mm in diameter that 
was separated by normal dermis from the main invasive component of a melanoma by distance of >0.5 
mm”.  The definition of microsatellite has been clarified and refined, so that in the Eighth Edition, there is 
no minimum size threshold or distance from the primary tumor that defines a microsatellite; it is simply 
defined as a microscopic cutaneous and/or subcutaneous metastasis adjacent to or deep to and 
completely discontinuous from a primary melanoma with unaffected stroma occupying the space 
between, identified on pathological examination of the primary tumor site.  Fibrous scarring and/or 
inflammation noted between an apparently separate nodule and the primary tumor (rather than normal 
stroma) may represent regression of the intervening tumor; if these findings are present, the nodule is 
considered to be an extension of the primary tumor and not a microsatellite.  Although occasionally seen 
in the primary melanoma diagnostic biopsy specimen, microsatellites, when present, are more commonly 
identified in the wide excision specimen. 
Metastatic melanoma in lymph nodes without a known primary tumor  
Patients presenting with melanoma in one or more lymph nodes without a known primary tumor 
were not included in the International Melanoma Database constructed for the analyses informing the 
Eighth Edition.  However, based on data from the published literature (including from patients diagnosed 
before 199871-73) and analysis of patients presenting to Melanoma Institute Australia since 1998,73 such 
patients had an equivalent or slightly better survival than patients with a known primary tumor who 
presented with a similar number of clinically-detected tumor-involved nodes.  The AJCC Melanoma 
Expert Panel recommended that such patients be assigned to the corresponding N category based on 
the number of lymph nodes containing metastatic disease and the presence or absence of satellite, 
microsatellite or in-transit metastases.  Until additional data are available, melanoma patients with an 
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unknown primary with N1b disease should be staged as IIIB whereas all other N categories should be 
staged as IIIC. 
  
The M category 
For the Eighth Edition, the Melanoma Expert Panel concluded that because of the rapidly 
changing and still evolving landscape for the management of patients with Stage IV melanoma, it was 
premature to embark on a broad-based analytic initiative based on new data from patients treated in 
recent years.  Instead, the legacy Seventh Edition AJCC Stage IV international melanoma database was 
used for the Eighth Edition as the primary data source (and no new analyses were conducted), 
supplemented by published contemporary clinical trial data.6-21  In the Eighth Edition, M category 
definitions were clarified and refined and a new category for patients with central nervous system (CNS) 
metastases was added (M1d).  For patients with distant metastases, M1 is defined by both anatomic site 
of distant metastatic disease and serum lactate dehydrogenase level (LDH) for all anatomic site 
subcategories.  
Anatomic site(s) of distant metastatic disease  
The anatomic site(s) of metastasis is used to assign patients to one of four (previously three) M 
subcategories:  M1a, M1b, M1c and, new to the Eighth Edition, M1d (Table 4).  The definition of each M1 
anatomic site subcategory was also clarified.  Patients with distant metastasis to skin, subcutaneous 
tissue, muscle or distant lymph nodes, regardless of serum LDH level, are categorized as M1a.  Patients 
with metastasis to lung (with or without concurrent metastasis to skin, subcutaneous tissue, muscle or 
distant lymph nodes and regardless of serum LDH level) are categorized as M1b.  Patients with 
metastases to any other visceral site(s) (exclusive of the CNS) are designated as M1c.  New to the 
Eighth Edition, patients with metastases to the CNS (i.e., involving the brain, spinal cord, leptomeninges, 
or other components of the CNS)36 are designated as M1d (irrespective of the presence of metastatic 
disease at other sites); these patients were previously designated as M1c in the Seventh Edition.  This 
revision to include an M1d category reflects the expert panel’s assessment that, in addition to the 
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historically poor overall survival outcome for patients with CNS metastases, contemporary clinical trial 
eligibility and exclusion criteria, as well as stratification and analysis, are often based on the 
presence/absence of CNS disease.6-21, 74, 75  This additional level of granularity in the M category 
therefore better “maps” to contemporary clinical practice and clinical trial decision-making and analysis. 
Serum LDH level  
In the Seventh Edition, an elevated LDH was used to categorize a patient as M1c, regardless of 
anatomic site(s) of metastatic disease, given its significance as an independent adverse predictor of 
survival among patients with Stage IV disease.  LDH remains a clinically significant factor associated 
with response, progression-free survival, MSS and overall survival in the contemporary treatment era of 
targeted and immune therapies.76-78  In the Eighth Edition, an elevated LDH level no longer 
independently defines M1c disease.  Instead, in order to better codify the impact of anatomic site and 
LDH level, descriptors were added to the M1 subcategory designation to indicate LDH status (designated 
as “(0)” for not elevated and “(1)” for elevated) for each M1 subcategory (Table 4).   
 
The Stage Groups 
As in prior editions of the AJCC Cancer Staging Manual, both clinical and pathological 
classifications are employed in melanoma staging.  In the Eighth Edition, clinical staging includes 
microstaging of the primary melanoma – as a standard practice, after resection of the primary melanoma 
– and clinical/radiologic assessment for regional and distant metastases, as well as biopsies performed 
to assess for regional and distant metastases as appropriate (Table 5).  There are no substages for 
clinical Stage III melanoma.  Pathological staging includes all clinical staging information, as well as any 
additional staging information derived from the wide excision (surgical) specimen that constitutes primary 
tumor surgical treatment, and pathological information about the clinically node-negative regional lymph 
nodes after SLN biopsy, with or without completion lymph node dissection (CLND), or therapeutic lymph 
node dissection for clinically evident regional lymph node disease (Table 6).  In patients who undergo 
SLN biopsy and have a clinically occult regional lymph node metastasis identified by SLN biopsy, but 
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additional surgery in the form of a CLND is not performed, according to the Eighth Edition Principles of 
Cancer Staging (Chapter 1 of the Eighth Edition AJCC Cancer Staging Manual55) and the Eighth Edition 
melanoma chapter36, category pN1a(sn) is assigned to specify that CLND was not performed.  If a CLND 
is performed, such patients would be assigned to subcategory pN1a (or another pN>0 subcategory 
depending on the total number of tumor-involved lymph nodes), to distinguish these two clinical 
scenarios and to improve granularity in coding for clinical and analytic purposes.36, 58 
Due in part to the low overall likelihood of nodal metastasis and lack of uniformly accepted criteria 
for SLN biopsy in T1 melanoma, neither pathological Stage 0 (melanoma in situ, Tis) nor T1 melanoma 
requires SLN biopsy to complete pathological staging among patients with clinically node-negative 
melanomas.  Instead, cN information is used to assign the pathological stage for T1 melanomas if SLN 
biopsy is not performed.  
The MSS for all patients stratified by pathological stage groups I to III is shown in Figure 5.  
Patients with Stages I, II, and III disease had 5- and 10-year MSS of 98% and 95%, 90% and 84%, and 
77% and 69%, respectively, and were overall slightly improved compared to patients who had similar 
stages of melanoma in the Seventh Edition analyses.25, 37  
 
Stages I and II subgroupings 
For pathological T category stage groups, 5- and 10-year MSS ranged from 99% and 98% in 
patients with Stage IA melanoma, respectively, to 82% and 75% in patients with Stage IIC disease 
(Figure 6).  As in the Seventh Edition, patients with clinical T1b N0 melanoma are included in clinical 
Stage IB.  In contrast, patients with pathological T1b N0 melanoma are included in pathological Stage IA 
(and not IB as in the Seventh Edition) (Table 6).  This stage grouping reflects the better survival of T1b 
patients with pathologically negative nodes, since if SLN biopsy was performed it only includes those 
with a tumor-negative SLN (i.e., T1b pN1 patients would be Stage III), compared with a group of T1b 
patients who were only clinically staged.  Five- and 10-year MSS were 97% and 93%, respectively, for 
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patients with clinical T1b N0 melanoma, compared to 99% and 96% 5- and 10-year MSS, respectively, 
for patients with pathological T1b N0 melanoma. 
Stage III subgroupings 
In the Seventh Edition, both regional node factors (number of nodes involved, microscopic versus 
macroscopic node involvement) as well as primary tumor ulceration, determined Stage III groups.  
Although N category alone predicts MSS in the Eighth Edition analysis (Figure 3), the Melanoma Expert 
Panel hypothesized that more accurate prognostic estimates could be obtained by including both T 
category factors, tumor thickness and ulceration status, along with the number of tumor-involved lymph 
nodes and whether they were detected clinically or were clinically occult (i.e., positive SLN), and the 
presence of microsatellite, satellite, and/or in-transit metastases (i.e., 9 N categories; Table 3).  This was 
evaluated using recursive partitioning analysis.  Initially, 8 pathological Stage III subgroups were created, 
including three “pairs” of subgroups that had similar 5-year MSS (data not shown).  Based on 
discussions by the Melanoma Expert Panel that explored the relative merits of “grouping” versus 
“splitting”, and the observation that adoption of five N stage groups would result in a total of 11 overall 
stage groups across T, N, and M (5+5+1=11) which would not conform to the total number of stage 
groups across the broad AJCC cancer disease site landscape, the 8 subgroups were combined to create 
four Stage III subgroups that maintained the overall prognostic heterogeneity of the base model (Figure 
7).  As such, these four subgroups stratify patients with Stage III melanoma in the Eighth Edition, 
compared to the three subgroups that were used to stratify Stage III patients in the Seventh Edition.25, 37  
A clinic workstation guide to combining T and N categories into Stage III subgroups is provided in Figure 
8 (see also Supplementary Figure 1 for a black and white version).  Five-year MSS according to Stage 
III subgroups ranges from 93% in Stage IIIA patients (1-3 clinically occult tumor-involved SLNs [N1a or 
N2a] and T1a, T1b or T2a primaries) to 32% for Stage IIID patients (patients with a thick and ulcerated 
primary [T4b] and either four or more tumor-involved regional nodes [N3a or N3b] or two or more tumor-
involved nodes and evidence of microsatellite, satellite or in-transit metastases [N3c]) (Figure 7).  In the 
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Seventh Edition, 5-year MSS for Stages IIIA, IIIB, and IIIC disease were 78%, 59% and 40%, 
respectively.37  These differences, particularly for patients with Stage IIIA disease, have implications for 
clinical decision-making and counseling, as well as the design, eligibility, stratification, and analysis of 
adjuvant therapy clinical trials. 
Distant Metastases (Stage IV) 
Although revisions to the M category have been implemented in the Eighth Edition, as described 
in detail above (Tables 4, 5 and 6), no M stage subgroups were proposed and no new data have thus far 
been analyzed.  This is because the availability of contemporary data is limited and because survival 
differences among patients with Stage IV melanoma historically were small (before the recent revolution 
in treatment options for patients with advanced melanoma).  It is anticipated that, as recently-introduced 
systemic therapies gain a foothold in the treatment repertoire of patients with advanced disease and 
even better treatment modalities become available, Stage IV survival outcomes will continue to improve.  
An international Stage IV melanoma database is planned in the future to explore this new and evolving 
treatment landscape for patients with advanced disease. 
 
ADDITIONAL RECOMMENDATIONS  
Multiple primary melanomas – It is well established that patients may be diagnosed with 
synchronous or metachronous primary melanomas.  In general, according to the Eighth Edition AJCC 
Principles of Cancer Staging,58 when patients present with multiple primary cutaneous melanomas, 
each is considered a different primary site and each is categorized separately.  In the uncommon clinical 
scenario where patients who harbor regional node metastases have multiple primary melanomas 
draining to the same regional node basin, the primary tumor with the highest T category should be 
assigned as the originating primary tumor with respect to the nodal metastases; if distant metastases 
are present, the primary tumor with the highest N category (or the highest T category if N0) should be 
assigned as the origin of the distant metastases.58  Moreover, in patients with multiple primary 
Page 24 of 115CA: A Cancer Journal for Clinicians
This article is protected by copyright. All rights reserved.
A
cc
ep
te
d 
A
rt
ic
le
 
 25
melanomas, the record d stage should map to the highest stage group of any of the primary tumors.  
According to the Principles of Cancer Staging,58 if there are multiple synchronous melanomas with no 
evidence of metastatic disease, the assigned category is based on the tumor with the highest T 
category, and by convention, the m suffix is used.  For example, T2a(m) would be used to describe a 
1.4 mm, non-ulcerated melanoma diagnosed synchronously with a 0.7 mm, non-ulcerated melanoma.  
Alternatively, another acceptable approach is to designate the number of primary tumors instead of the 
m suffix (i.e., T2a(2) in the above example).58  To the extent possible, if the number of synchronous 
multiple primary melanomas at presentation is known, this latter approach is preferred by the Melanoma 
Expert Panel. 
Other important primary tumor factors – Although detailed discussion is beyond the scope of 
this article, in addition to the variables discussed (e.g., tumor thickness, ulceration, mitotic rate), the 
Melanoma Expert Panel recommends routine collection of multiple other known or putative primary tumor 
factors:  level of invasion, tumor-infiltrating lymphocytes, lymphovascular invasion, and neurotropism.  
The interested reader is referred to a comprehensive description and discussion of these and other 
factors in the melanoma chapter of the Eighth Edition AJCC Cancer Staging Manual.36 
SLN microscopic tumor burden – There is significant and growing evidence that microscopic 
tumor burden in the sentinel node is prognostically important.79-91  Sentinel node tumor burden can be 
assessed by a variety of micromorphometric parameters including the maximum size of the largest 
metastasis, maximum subcapsular depth (also known as tumor penetrative depth89 of the deposits and 
measured from the inner surface of the lymph node capsule to the deepest intranodal tumor cell), the 
microanatomic location of sentinel node tumor deposits, the percentage cross-sectional area of the 
sentinel node that is involved and the presence of extranodal extension.  In various studies, one or more 
of these parameters has predicted survival in SLN positive patients.79-91  
The impact of extent of SLN tumor burden (based on largest maximum dimension of the largest 
discrete metastatic melanoma deposit) was assessed for the subset of patients with known SLN tumor 
burden in the IMDDP.  In univariate analysis, increasing SLN tumor burden was associated with reduced 
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MSS (Figure 9).  Although this histopathological parameter is not a formal staging criterion for the N 
category in the Eighth Edition, documentation of SLN tumor burden is an important prognostic factor that 
will be included in and likely guide the development of future prognostic models and ultimately validated 
clinical tools (e.g., calculators, nomograms, etc.) for patients with regional metastatic disease.   
Microscopic SLN tumor burden has already been implemented as an inclusion criterion in some 
clinical trials (e.g., EORTC 18071 - adjuvant ipilimumab in stage III23, 24 and EORTC1325 - adjuvant 
pembrolizumab in stage III24).  In these trials, patients with a single positive SLN must have a 
microscopic tumor burden >1mm in diameter, based on the relatively worse prognosis of this patient 
subgroup.  
Based on the currently available evidence, the AJCC Melanoma Expert Panel recommends that, 
as a minimum, the single largest maximum dimension (measured in millimeters to the nearest 0.1 mm 
using an ocular micrometer) of the largest discrete metastatic melanoma deposit in sentinel nodes be 
recorded in pathology reports.36  To further advance this field, the AJCC Melanoma Expert Panel and 
International Melanoma Pathology Study Group plan to continue efforts to harmonize and standardize 
assessment and reporting of SLN tumor burden.  Planned IMDDP analyses will also further explore the 
prognostic impact of SLN tumor burden. 
Number of distant metastatic sites and extent of distant metastatic disease burden – The 
number of metastases at distant sites has previously been documented as an important prognostic 
factor. 77, 92-95  This was also confirmed in previous preliminary multivariable analyses using the Seventh 
Edition AJCC stage IV melanoma database.  However, this feature was not incorporated into the Eighth 
Edition as a formal staging criterion due in part to significant variability in the deployment of diagnostic 
imaging to comprehensively search for distant metastases (ranging from a chest x-ray in some centers to 
high-resolution double-contrast CT, PET/CT, and MRI in others) as well as the heterogeneity with which 
extent of disease results are codified across databases.  Until recording of the indications for and types 
of investigations used and extent of distant metastatic disease are better standardized, the Melanoma 
Expert Panel concluded that number of metastases cannot reproducibly be used for staging purposes.   
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Approach to staging patients following neoadjuvant (“up front”) therapy – Historically, 
surgery represented the mainstay of treatment for patients with cutaneous melanoma.  For several solid 
tumors, neoadjuvant therapy (systemic therapy prior to surgical resection) is often used as part of 
multidisciplinary treatment approaches for patients with locally advanced and/or regional disease, and for 
others an “up front” approach using systemic therapy (without a definitive plan for surgery to follow) is 
employed.96  The availability of effective systemic therapies has greatly expanded potential treatment 
approaches for patients with unresectable and regionally advanced melanoma over the past several 
years and has led to tremendous interest in leveraging these clinical advances to develop neoadjuvant 
strategies for melanoma patients with locally advanced or metastatic disease.  To stage such patients 
after treatment, the Eighth Edition Principles of Cancer Staging includes a posttherapy or post 
neoadjuvant therapy classification – yTNM -- that includes T, N, and M categorization after systemic or 
radiation treatment intended as definitive therapy (ycTNM), or after neoadjuvant therapy followed by 
planned surgery (ypTNM).58  Although this has been an infrequently utilized classification in melanoma to 
date, given that a robust portfolio of neoadjuvant clinical trials in melanoma patients are currently under 
way, and still more are planned, the “y” classification schema may prove useful in characterizing such 
patients, and the information can be compared to clinical stages assigned to patients before the start of 
neoadjuvant therapy.  Future analyses will likely allow refinement of this not yet widely used classification 
schema.  
Approach to staging patients following recurrence/retreatment – By definition, clinical and 
pathological classification according to the AJCC staging system occurs at initial melanoma presentation.  
Thus, those who have regional node or non-nodal regional metastases at the time of initial presentation 
are characterized as having Stage III disease, and those who present with distant metastases at the time 
of initial presentation are characterized as having Stage IV disease.  To accommodate staging for 
patients who have recurred, the Eighth Edition Principles of Cancer Staging also includes an additional 
classification schema for patients who recur – rTNM – that is further divided into “r-clinical” (rcTNM) and 
“r-pathological” (rpTNM) stages.  Such an approach may be useful to better characterize extent of 
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disease along an individual melanoma patient’s disease continuum.58  As this staging classification is to 
date relatively unknown and infrequently used by the global melanoma community, future analyses will 
likely inform revisions of this classification schema for patients with recurrent melanoma. 
 
CONCLUSIONS 
In the Eighth Edition AJCC Staging System for cutaneous melanoma, particular attention was 
directed to clarifying major themes and terminology, introducing clinically relevant revisions and creating 
a new, contemporary international database.  The Melanoma Expert Panel focused most of its attention 
on evidence-based revisions of Stages I to III melanoma for the Eighth Edition AJCC Cancer Staging 
Manual, and established a framework for the development of robust and iteratively refined clinical 
prognostic models that will assist in the development of clinical tools to ultimately enhance clinical 
decision making.  Importantly, based on analyses of this contemporary melanoma database, survival 
outcomes for equivalent stage groupings were substantially higher than for similar stage groups of 
patients in prior Editions, including the Seventh Edition, with implications for clinical decision-making and 
clinical trial design, eligibility, stratification, and analysis. 
 Given the rapidly evolving landscape of treatment of Stage IV melanoma in recent years, which 
already has resulted in significantly improved progression-free and overall survival for patients, the 
Melanoma Expert Panel strategically paused and did not establish a Stage IV database or perform 
analyses of Stage IV patients.  Instead new, clinically relevant M category criteria were introduced into 
the Eighth Edition that will facilitate refined collection of Stage IV data including more precise data 
collection for patients with CNS metastases.  These new criteria will be essential to support future 
assessment of prognosis, as well as clinical trial design, eligibility, stratification, and analysis, for patients 
with advanced melanoma.  Strategic development of analytic efforts for the Stage IV melanoma 
population in the current new era of effective targeted therapies and immunotherapy is now under way as 
part of the IMDDP.  These analyses are expected not only to improve prognostic assessment for patients 
Page 28 of 115CA: A Cancer Journal for Clinicians
This article is protected by copyright. All rights reserved.
A
cc
ep
te
d 
A
rt
ic
le
 
 29
with advanced disease but also to inform further revisions of the staging system, and facilitate the 
development of clinical tools in the foreseeable future. 
 Additional enhancements to the Eighth Edition melanoma staging system, including yTNM and 
rTNM classifications, will enable contemporary melanoma patients to be accurately risk stratified across 
the disease continuum.  This will assist clinicians and patients in clinical management planning and 
enhance the design, conduct and analysis of clinical trials that should ultimately lead to improved patient 
outcomes.  Undoubtedly, melanoma staging will continue to evolve as new prognostic factors and 
evidence-based approaches – including integration of clinical, pathological, molecular and immunological 
endpoints – are developed, refined, and validated.  
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Tables 
Table 1. A summary of the major changes introduced and highlights of the Eighth Edition of the 
AJCC Melanoma Staging System.  
Change Details of Change/Highlight 
Definition of Primary Tumor 
(T) 
All principal T category tumor thickness ranges maintained, but T1 now 
subcategorized by tumor thickness strata at 0.8mm threshold 
Definition of Primary Tumor 
(T) 
Tumor mitotic rate removed as a staging criterion for T1 tumors 
• T1a melanomas now defined as non-ulcerated and less than 
0.8mm in thickness;  
• T1b now defined as melanomas 0.8mm to 1.0mm in thickness 
regardless of ulceration status OR ulcerated melanomas less 
than 0.8mm in thickness 
Definition of Primary Tumor 
(T) 
T0 definition has been clarified – T0 should be used to designate when 
there is no evidence of a primary tumor, or the site of the primary tumor 
is unknown (e.g., in a patient who presents axillary metastasis with no 
known primary tumor); staging may be based on the clinical suspicion of 
the primary tumor with the tumor categorized as T0 (Tis, not T0, 
designates melanoma in situ) 
Definition of Primary Tumor 
(T) 
Tumor thickness measurements now recorded to the nearest 0.1mm, not 
the nearest 0.01mm, because of impracticality and imprecision of 
measurements particularly for tumors >1mm thick. Tumors ≤1mm may 
be measured to the nearest 0.01mm when practical, but should be 
reported rounded to the nearest 0.1mm (e.g., melanomas measured to 
be anywhere in the range from 0.75mm to 0.84mm are reported as 
0.8mm in thickness (and hence T1b) 
Definition of Primary Tumor 
(T) 
Tis (melanoma in situ), T0 (no evidence of or unknown primary tumor), 
and TX (tumor thickness cannot be determined) may now be used as the 
T category designation for stage groupings 
Definition of Regional Lymph 
Node (N) 
Number of metastasis-containing regional lymph nodes maintained 
Definition of Regional Lymph 
Node (N) 
Previously empirically defined “microscopic” and “macroscopic” 
descriptors redefined as “clinically occult” (i.e., clinical Stage I-II with 
nodal metastasis determined at sentinel node biopsy) and “clinically 
apparent” regional node disease (clinical Stage III), respectively 
Definition of Regional Lymph 
Node (N) 
Sentinel node tumor burden is considered a regional disease prognostic 
factor that should be collected for all patents with positive sentinel 
nodes, but is not used to determine N category groupings  
Definition of Regional Lymph 
Node (N) 
Non-nodal regional disease, including microsatellites, satellites, and in-
transit cutaneous and/or subcutaneous metastases more formally 
stratified by N category according to # of tumor involved lymph nodes 
(Presence of microsatellites, satellites, or in-transit metastases now 
categorized as N1c, N2c, or N3c based on number of synchronous 
tumor-involved regional lymph nodes, if any) 
Definition of Regional Lymph 
Node (N) 
“Gross” extranodal extension no longer used as an N staging criterion 
(but the presence of “matted nodes” is retained) 
Definition of Distant 
Metastasis (M) 
M1 now defined by both anatomic site of distant metastatic disease and 
serum lactate dehydrogenase (LDH) value for all anatomic site 
subcategories 
Definition of Distant 
Metastasis (M) 
Descriptions of distant anatomic sites of disease clarified in M 
subcategories 
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Change Details of Change/Highlight 
Definition of Distant 
Metastasis (M) 
Descriptors now added to M1 subcategory designation that provides 
LDH values (designated as “0” for “not elevated” and “1” for “elevated” 
level) for all sites of distant disease; e.g., skin/soft tissue/nodal 
metastasis with elevated LDH now M1a(1), not M1c 
Definition of Distant 
Metastasis (M) 
New M1d designation added to include distant metastasis to central 
nervous system (CNS), with or without any other distant sites of disease; 
M1c no longer includes CNS metastasis 
Definition of Distant 
Metastasis (M) 
Elevated LDH level no longer defines M1c 
AJCC Prognostic Stage 
Groups 
No overall change in T subcategories, but definition of T1a and T1b 
refined 
AJCC Prognostic Stage 
Groups 
N category now composed of five substages rather than three, and 
Stage III subgroupings are based on multivariable models including T 
category elements (tumor thickness and ulceration) and N category 
elements (# of nodes, satellites/in-transits/microsatellites) demonstrating 
significant impact of primary tumor factors in assigning N substage  
AJCC Prognostic Stage 
Groups 
Clarified that stage IV not further substaged (i.e., M1c is stage IV, not 
stage IVC) 
 
*Used with permission of the American Joint Committee on Cancer (AJCC), Chicago, Illinois. The original 
and primary source for this information is the AJCC Cancer Staging Manual, Eighth Edition (2017) 
published by Springer International Publishing. 
 
Gershenwald, J.E., Scolyer, R.A., et al. Melanoma of the Skin. In: Amin, M.B., Edge, S.B., Greene, F.L., 
et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017: 563-585 
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Table 2. Definition of Primary Tumor (T)  
T Category Thickness Ulceration status 
TX: primary tumor thickness 
cannot be assessed (e.g., 
diagnosis by curettage) 
 
Not applicable  Not applicable 
T0: no evidence of primary tumor 
(e.g., unknown primary or 
completely regressed 
melanoma) 
 
Not applicable 
Not applicable 
Tis (melanoma in situ) Not applicable Not applicable 
T1 ≤1.0 mm Unknown or unspecified 
     T1a <0.8 mm Without ulceration  
     T1b 
<0.8 mm 
0.8–1.0 mm 
With ulceration  
With or without ulceration 
T2 >1.0–2.0 mm Unknown or unspecified 
     T2a >1.0–2.0 mm Without ulceration  
     T2b >1.0–2.0 mm With ulceration 
T3 >2.0-4.0 mm Unknown or unspecified 
     T3a >2.0–4.0 mm Without ulceration 
     T3b >2.0–4.0 mm With ulceration 
T4 >4.0 mm Unknown or unspecified 
     T4a >4.0 mm Without ulceration 
     T4b >4.0 mm With ulceration 
 
*Adapted with permission of the American Joint Committee on Cancer (AJCC), Chicago, Illinois. The 
original and primary source for this information is the AJCC Cancer Staging Manual, Eighth Edition 
(2017) published by Springer International Publishing. 
 
Modified from Gershenwald, J.E., Scolyer, R.A., et al. Melanoma of the Skin. In: Amin, M.B., Edge, S.B., 
Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017: 563-585 
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Table 3. Definition of Regional Lymph Node (N) 
 
Extent of regional lymph node and/or  
lymphatic metastasis 
N Category Number of tumor-involved regional lymph node 
Presence of in-
transit, satellite, 
and/or microsatellite 
metastases 
NX Regional nodes not assessed (e.g., SLN biopsy not performed, 
regional nodes previously removed for another reason)  
Exception: pathological N category is not required for T1 
melanomas, use cN. 
   No 
N0 No regional metastases detected     No 
N1 One tumor-involved node or any number of 
in-transit, satellite, and/or microsatellite 
metastases with no tumor-involved nodes 
 
     N1a  One clinically occult (i.e., detected by SLN biopsy)    No 
     N1b  One clinically detected    No 
     N1c  No regional lymph node disease    Yes 
N2 Two or three tumor-involved nodes or any 
number of in-transit, satellite, and/or 
microsatellite metastases with one tumor-
involved node  
 
     N2a  Two or three clinically occult (i.e., detected by SLN biopsy)     No 
     N2b  Two or three, at least one of which was clinically detected     No 
     N2c One clinically occult or clinically detected    Yes 
N3 Four or more tumor-involved nodes or any 
number of in-transit, satellite, and/or 
microsatellite metastases with two or more 
tumor-involved nodes, or any number of 
matted nodes without or with in-transit, 
satellite, and/or microsatellite metastases   
 
     N3a  Four or more clinically occult (i.e., detected by SLN biopsy)     No 
     N3b Four or more, at least one of which was clinically detected, or 
presence of any number of matted nodes 
   No 
     N3c Two or more clinically occult or clinically detected and/or 
presence of any number of matted nodes 
   Yes 
 
*Adapted with permission of the American Joint Committee on Cancer (AJCC), Chicago, Illinois. The 
original and primary source for this information is the AJCC Cancer Staging Manual, Eighth Edition 
(2017) published by Springer International Publishing. 
 
Modified from Gershenwald, J.E., Scolyer, R.A., et al. Melanoma of the Skin. In: Amin, M.B., Edge, S.B., 
Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017: 563-585 
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Table 4. Definition of Distant Metastasis (M)  
    M Criteria   
M Category Anatomic site LDH level 
M0 No evidence of distant 
metastasis 
Not applicable 
M1 Evidence of distant metastasis See below 
     M1a  Distant metastasis to skin, soft 
tissue including muscle, and/or 
nonregional lymph node  
Not recorded or 
unspecified 
 M1a(0) Not elevated 
 M1a(1) Elevated 
     M1b Distant metastasis to lung with or 
without M1a sites of disease  
Not recorded or 
unspecified 
 M1b(0) Not elevated 
 M1b(1) Elevated 
     M1c  Distant metastasis to non-CNS 
visceral sites with or without M1a 
or M1b sites of disease  
Not recorded or 
unspecified 
 M1c(0) Not elevated 
 M1c(1) Elevated 
     M1d  Distant metastasis to CNS with 
or without M1a, M1b, or M1c 
sites of disease 
Not recorded or 
unspecified 
 M1d(0) Normal 
 M1d(1) Elevated 
Suffixes for M category: (0) LDH not elevated, (1) LDH elevated. 
No suffix is used if LDH is not recorded or is unspecified.  
 
*Used with permission of the American Joint Committee on Cancer (AJCC), Chicago, Illinois. The original 
and primary source for this information is the AJCC Cancer Staging Manual, Eighth Edition (2017) 
published by Springer International Publishing. 
 
Gershenwald, J.E., Scolyer, R.A., et al. Melanoma of the Skin. In: Amin, M.B., Edge, S.B., Greene, F.L., 
et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017: 563-585 
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Table 5. AJCC Clinical Prognostic Stage Groups (cTNM) 
When T is& And N is& And M is& Then the clinical 
stage group is& 
Tis N0 M0 0 
T1a N0 M0 IA 
T1b N0 M0 IB 
T2a N0 M0 IB 
T2b N0 M0 IIA 
T3a N0 M0 IIA 
T3b N0 M0 IIB 
T4a N0 M0 IIB 
T4b  N0 M0 IIC 
Any T, Tis ≥N1  M0 III 
Any T Any N M1 IV 
 
*Used with permission of the American Joint Committee on Cancer (AJCC), Chicago, Illinois. The original 
and primary source for this information is the AJCC Cancer Staging Manual, Eighth Edition (2017) 
published by Springer International Publishing. 
 
Gershenwald, J.E., Scolyer, R.A., et al. Melanoma of the Skin. In: Amin, M.B., Edge, S.B., Greene, F.L., 
et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017: 563-585 
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Table 6. AJCC Pathological (pTNM) Prognostic Stage Groups 
 
When T is& And N is& And M is& Then the 
pathological stage 
group is& 
Tis N0 M0 0 
T1a N0 M0 IA 
T1b N0 M0 IA 
T2a N0 M0 IB 
T2b N0 M0 IIA 
T3a N0 M0 IIA 
T3b N0 M0 IIB 
T4a N0 M0 IIB 
T4b N0 M0 IIC 
T0 N1b, N1c M0 IIIB 
T0 N2b, N2c, N3b or N3c M0 IIIC 
T1a/b–T2a N1a or N2a M0 IIIA 
T1a/b–T2a N1b/c or N2b M0 IIIB 
T2b/T3a N1a–N2b M0 IIIB 
T1a–T3a N2c or N3a/b/c M0 IIIC 
T3b/T4a Any N ≥N1 M0 IIIC 
T4b N1a–N2c M0 IIIC 
T4b N3a/b/c M0 IIID 
Any T, Tis Any N M1 IV 
Pathological Stage 0 (melanoma in situ) and T1 do not require pathological evaluation of lymph nodes to 
complete pathological staging; use cN information to assign their pathological stage. 
 
*Used with permission of the American Joint Committee on Cancer (AJCC), Chicago, Illinois. The original 
and primary source for this information is the AJCC Cancer Staging Manual, Eighth Edition (2017) 
published by Springer International Publishing. 
 
Gershenwald, J.E., Scolyer, R.A., et al. Melanoma of the Skin. In: Amin, M.B., Edge, S.B., Greene, F.L., 
et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017: 563-585 
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Supplementary Table 1. Details of the International Melanoma Database and Discovery Platform 
(IMDDP) – Contributors to Current Analysis 
 
 
  
 Location 
 
Institution 
 
Continent 
 
City, State, Country 
No. of Patients 
Contributed to Wave I 
IMDDP Analysis 
 
Melanoma Institute Australia 
 
 
Australia 
 
Sydney, New South 
Wales, Australia 
 
17,276 
 
Melbourne Melanoma 
Project 
 
 
Australia Melbourne, Victoria, 
Australia 
1,408  
Department of Dermatology, 
National and Kapodistrian 
University of Athens School 
of Medicine, Andreas Sygros 
Hospital 
 
Europe 
 
Athens, Greece 
 
468 
 
 
Fondazione IRCCS Istituto 
Nazionale dei Tumori 
 
Europe 
 
Milan, Italy 
 
6,537 
 
 
Instituto Valenciano de 
Oncologia 
Europe 
 
Valencia, Spain 1,392 
 
 
National and Kapodistrian 
University of Athens School 
of Medicine  - General 
Hospital of Athens – Laiko 
 
Europe 
 
Athens, Greece 
 
1,205  
Veneto Institute of 
Oncology-IOV 
 
 
Europe 
 
Padova, Italy 
 
2,954  
John Wayne Cancer Institute 
 
North America Santa Monica, California, 
USA 
6,228  
The University of Texas MD 
Anderson Cancer Center 
North America Houston, Texas, USA 8,023  
 
Winship Cancer Institute of 
Emory University 
North America Atlanta, Georgia, USA 1,495  
Total   46,986  
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Supplementary Table 2 - International Melanoma Database and Discovery Platform  
Data Dictionary. Data elements used for analyses that informed the Eighth Edition (Stages I-III) 
 
Variable Description Acceptable Values 
Patient Demographics   
Collaborator_Patient_ID 
Unique patient identifier for the home institution 
database (de-identified) 
Home institution 
format 
DOB Patient date of birth Date 
Patient_Sex Patient sex 
Male 
Female 
Other/Unknown 
Last_Vital_Date Date of last follow-up Date 
Last_Vital_Status Status at last follow-up  
Alive                                                                                                                        
Deceased 
Cause_Death Cause of death  
Melanoma                       
Other                                                                                          
Not applicable 
   
T Category    
KnownPrimary_DX_Staging_Date Date of diagnosis of primary Date 
Primary_Site Anatomic site of primary 
Home institution 
format 
Breslow_Thickness_MM Breslow thickness (mm)* of  primary Numeric 
Ulceration Ulceration status of primary 
Absent                                                                
Present                                    
Unknown 
Mitoses_PerMM2 Mitoses/mm2  Numeric 
   
N Category   
SLNB_Status Sentinel-lymph node status  
Negative                                                              
Positive                                                     
Not conducted 
Clinical_Detection 
If regional nodes are involved, was there clinical 
detection of regional lymph nodes  
No = detected by SLN biopsy                                                                            
Yes                                                                              
No  
Unknown
Overall_Positive_Nodes Total number of tumor-involved lymph nodes** Numeric 
Largest_Metastatic_MM 
Largest diameter of the largest metastatic deposit 
in the tumor-involved sentinel node(s) (mm)* 
Numeric 
Tumor_Nodal_Location 
Location(s) of the metastatic deposit(s) in the 
sentinel node 
Subcapsular                                         
Intraparenchymal                                                          
Both                                                                                              
Unknown 
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Variable Description Acceptable Values 
Extranodal_Extension 
Presence of extranodal extension** of regional 
node(s) at diagnosis 
Absent                                      
Present                                                         
Unknown 
Microsatellites 
Presence of microsatellites in the primary tumor 
specimen (yes/no) at diagnosis 
Absent                                                       
Present                                                         
Unknown 
Intransit 
Presence of in-transit and/or satellite lesions at 
diagnosis 
Absent                                                                
Present                          
Unknown 
*At the level of precision used by your institution and data team.  
**Including cumulative results from histopathological assessment of staging lymph node procedures, for 
example sentinel node biopsy and completion lymph node dissection OR lymph node biopsy and 
therapeutic lymph node dissection. 
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Figure Legends 
Figure 1.  Kaplan–Meier MSS curves according to T subcategory for patients with Stage I to II 
melanoma from the Eighth Edition international melanoma database. N0 patients have been filtered so 
that T2 to T4 patients were included only if SLN negative, whereas patients with T1N0 melanoma are 
included regardless of whether SLN biopsy was performed.  
 
Figure 2.  Kaplan–Meier MSS curves according to mitotic rate (mitoses per square millimeter) in patients 
with Stage I to II melanoma from the Eighth Edition international melanoma database. N0 patients have 
been filtered so that T2 to T4 patients were included only if SLN negative, whereas patients with T1N0 
melanoma were included regardless of whether SLN biopsy was performed. 
  
Figure 3.  Kaplan–Meier MSS curves according to N categories (A) and subcategories (B) from the 
Eighth Edition international melanoma database  
 
Figure 4.  Kaplan–Meier MSS curves according to the presence or absence of microsatellites, satellites, 
and/or in-transit metastases from the Eighth Edition international melanoma database. (Note: Intransit in 
figure means in-transit and/or satellite metastasis; both means microsatellites and/or in-transit and/or 
satellite metastasis.) 
 
Figure 5.  Kaplan–Meier MSS curves according to Stage in patients with Stage I to III melanoma from 
the Eighth Edition international melanoma database. 
 
Figure 6.  Kaplan–Meier MSS curves according to T category stage group for patients with Stage I to II 
melanoma from the Eighth Edition international melanoma database. N0 patients were filtered so that 
Comment [TG16]: Please check consistency 
of font sizes and styles in figures. There seems 
to be some inconsistency but I can’t be certain 
whether this reflects the original figures or the 
way they were joined in the pdf. 
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T2+ patients are included only if SLN negative, whereas patients with T1N0 melanoma are included 
regardless of whether SLN biopsy was performed.  
 
Figure 7.  Kaplan–Meier MSS curves according to Stage III subgroups from the Eighth Edition 
international melanoma database. 
 
Figure 8.  AJCC Eighth Edition Stage III subgroups based on T and N categories. 
 
 
Figure 9.  Kaplan–Meier MSS curves according to maximum dimension of sentinel node metastatic 
focus (millimeters) from the Eighth Edition international melanoma database. (Note – insufficient data 
exists to estimate 10-year MSS for patients with 2 mm to 4 mm maximum sentinel node metastatic 
focus). 
 
Supplementary Figure 1.  AJCC Eighth Edition Stage III subgroups based on T and N categories (black 
and white version). 
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ABSTRACT   
To update the melanoma staging system of the previous (Seventh) edition of the American Joint 
Committee on Cancer (AJCC) Cancer Staging Manual published in 2009, a large database was 
assembled comprising >46,000 patients from 10 centers worldwide with Stages I, II, and III melanoma 
diagnosed since 1998.  Based on analyses of this new database, the existing Seventh Edition AJCC 
Stage IV database, and contemporary clinical trial data, the AJCC Melanoma Expert Panel introduced 
several important changes to the TNM classification and stage grouping criteria.  These were 
incorporated into the Eighth Edition AJCC Cancer Staging Manual. Key changes include:  (1) tumor 
thickness measurements to be recorded to the nearest 0.1 mm, not the nearest 0.01 mm; (2) definitions 
of T1a and T1b revised (T1a, <0.8 mm without ulceration; T1b, <0.8 mm with ulceration or 0.8-1.0 mm 
with or without ulceration, or <0.8 mm with ulceration), with mitotic rate no longer a T category criterion; 
(3) pathological (but not clinical) Stage IA revised to include T1b N0 M0 (formerly pathological Stage IB); 
(4) N category descriptors “microscopic” and “macroscopic” for regional node metastasis redefined as 
“clinically occult” and “clinically apparent”; (5) prognostic Stage III groupings based on N category criteria 
and T category criteria (i.e., primary tumor thickness and ulceration) and increased from three to four 
subgroups (Stage IIIA-IIID); (6) definitions of N subcategories revised, with presence of microsatellites, 
satellites or in-transit metastases now categorized as N1c, N2c or N3c based on number of tumor-
involved regional lymph nodes, if any; (7) descriptors added to each M1 subcategory designation for LDH 
level (LDH elevation no longer automatically upstages to M1c); (8) a new M1d designation for 
metastases involving the central nervous system.  This evidence-based revision of the AJCC melanoma 
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 4 
staging system will guid  patient treatment, provide better prognostic estimates, and further refine 
eligibility and stratification of patients entering clinical trials.    
 
 
Keywords:  American Joint Committee on Cancer (AJCC), melanoma, database, TNM classification, 
staging, stage groupings, pathology, tumor thickness, ulceration, mitotic rate, regional lymph nodes, 
sentinel lymph node, visceral metastasis, brain metastasis, prognosis, survival  
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INTRODUCTION 
To improve the outcomes of patients with cutaneous melanoma, treatment based on accurate 
staging and patient stratification into clinically-relevant stage groups is fundamental.  Not only does 
staging inform prognostic assessment and clinical decision making, but it also facilitates centralized 
cancer registry reporting and the design, conduct and analysis of clinical trials.  
Since the early 1990s, a major advance in the management of patients with cutaneous melanoma 
involves the technique of lymphatic mapping and sentinel lymph node (SLN) biopsy;1 this is now routinely 
employed as a staging procedure2 for patients with T1b, T2, T3 and T4 (Eighth Edition) primary 
cutaneous melanomas and clinically negative regional lymph nodes in most melanoma treatment centers 
throughout the world.33  The frequency of SLN metastasis increases with increasing tumor thickness and 
other adverse clinicopathological prognostic factors.3-5  Clinical imaging technologies have also 
advanced, having become more sophisticated and more widely available, facilitating the detection of 
distant metastatic disease when it is of low volume and asymptomatic.  
More recently, based upon improved knowledge of both the molecular pathogenesis of melanoma 
and cancer immunology, there has been a revolution in the treatment of patients with advanced stage 
and unresectable melanoma.6-21  This has already resulted in major improvements in patient outcomes.33  
Two major new classes of effective systemic therapeutic agents are now in widespread clinical use:  
immunotherapies (e.g., checkpoint inhibitors against cytotoxic T lymphocyte antigen 4 (CTLA-4) and/or 
programmed death 1 (PD-1)) that enhance the natural host antitumor immune response, and molecularly 
targeted antitumor therapies (e.g., BRAF inhibitors alone or in combination with MEK inhibitors for the 
approximately 40 to 50% of patients with BRAFV600 mutant melanoma).22  Moreover, adjuvant therapy 
with anti-CTLA-4 significantly improves relapse-free survival and overall survival in stage III melanoma 
patients.23, 24  It is against this background that the American Joint Committee on Cancer (AJCC) 
appointed a Melanoma Expert Panel to undertake the task of revising the cutaneous melanoma staging 
system for the Eighth Edition of the AJCC Cancer Staging Manual. 
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 The Seventh Edition AJCC melanoma staging system (hereafter referred to as the Seventh 
Edition) has been widely adopted since its publication in 2009 and implementation in 2010.2, 25  For the 
Eighth Edition AJCC melanoma staging system (hereafter referred to as the Eighth Edition), a 
contemporary international database was assembled to provide an evidence-based rationale for 
revisions to the cutaneous melanoma staging system that would have more current applicability.33  The 
objective was to analyze detailed multi-institutional clinicopathological data collected in a standardized 
fashion to empirically establish T, N, and M categories and stage groupings for the Eighth Edition.  We 
report here the results of analyses using this large melanoma database, supplemented by analyses from 
the Seventh Edition AJCC Stage IV database and by contemporary clinical trial data.  These provided 
the evidence base for revisions of the Eighth Edition as well as the UICC Eighth Edition TNM 
Classification of Malignant Tumours.26  The revised T, N, and M categories and stage groupings are 
presented below.  To ensure that the necessary infrastructure is in place across the cancer care 
community, the Eighth Edition, originally published in October 2016, will not be formally implemented in 
the U.S. until January 1, 2018.27 
 
DATABASE and METHODS 
To assist the Eighth Edition Melanoma Expert Panel in its review of T and N categories and Stage 
I to III subgroupings, a protocol-based International Melanoma Database and Discovery Platform 
(IMDDP) was created at The University of Texas MD Anderson Cancer Center (MD Anderson), Houston, 
TX, USA.  This protocol was approved by the MD Anderson Institutional Review Board (IRB) and formal 
data use agreements were implemented across all participating institutions, each also having obtained 
approval from their own IRB.  This overall approach built upon collaborative efforts of the previous AJCC 
Melanoma Task Forces (renamed the AJCC Melanoma Expert Panel for the Eighth Edition) and an 
expanded network of national and international academic melanoma clinician–investigators representing 
institutions, cooperative groups, and tumor registries.  The database included de-identified patient 
records from 10 institutions in the United States, Europe and Australia, with well-annotated 
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clinicopathological and follow-up data for patients with Stages I to III melanoma at initial diagnosis, 
treated since 1998.  Importantly, the database reflected a contemporary clinical practice era during which 
the use of lymphatic mapping and SLN biopsy was well established in nearly all academic medical 
centers worldwide for patients considered at significant risk for occult regional node metastasis.  Patients 
treated in the pre-SLN era (i.e., pre-1990s) as well as the early SLN era (early through mid-1990s) were 
deliberately omitted.  During this latter period, SLN biopsy surgical techniques had evolved and matured 
(with development and implementation of a dual-modality intraoperative approach using blue dye and a 
radiotracer with gamma probe detection) and pathological assessment of the SLN (with widespread 
implementation of “enhanced” pathological assessment using step or serial sectioning and 
immunohistochemistry).1, 2, 28-32 
 For the analyses undertaken for the Eighth Edition, the database platform included the records of 
more than 46,000 melanoma patients (Supplementary Table 1).), of whom 43,792 qualified for analysis.  
Only data from patients for whom all relevant covariates (Supplementary Table 2) were known were 
included in the analyseseach analysis.  
 Given the unprecedented changes in the still rapidly evolving landscape of the management of 
patients with Stage IV melanoma, the Melanoma Expert Panel concluded that it was premature to 
embark on a broad-based analytic initiative involving data from Stage IV patients treated during the past 
8 years.  Instead, the legacy 7th Edition AJCC Stage IV international melanoma database containing 
details of approximately 10,000 patients who presented with or developed Stage IV disease was used as 
the primary data source for the 8th Edition, supplemented by published contemporary clinical trial data.6-21 
 
Statistical Analyses 
Melanoma-specific survival (MSS) was calculated from the date of initial melanoma diagnosis.  MSS 
curves were computed using the Kaplan-Meier method.  Multivariable analyses were conducted using 
Cox proportional hazards regression models and recursive partitioning analysis (RPA).  Analyses were 
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performed using S+ (Windows version 8.2, TIBCO, software, Inc.).  RPA was performed using the S+ 
“tree” libraries on the MSS null martingale residuals.  
 
MAJOR CHANGES 
Table 1 summarizes the major changes introduced for the T, N, and M categories and stage groupings in 
the Eighth Edition.  The rationale for these changes is described below. 
The T Category  
Breslow Tumor Thickness 
In prior editions of the AJCC Cancer Staging Manual,2, 25 it was implied (but not explicitly stated) 
that primary melanoma tumor thickness should be recorded to the nearest 0.01 mm.  This has been 
clarified in the Eighth Edition.  Based on consensus recommendations by the International Collaboration 
on Cancer Reporting33 and the International Melanoma Pathology Study Group, already widely adopted 
in the pathology community,34 thickness measurements should be recorded to the nearest 0.1 mm, not 
the nearest 0.01 mm, because of the impracticality and imprecision of measurements,34 particularly for 
tumors >1 mm thick, and the reality that tumor thickness may vary by 0.1 mm or more between different 
histological tissue sections cut from the same paraffin tissue block of the tumor.35  Tumors ≤1mm thick 
may initially be measured to the nearest 0.01 mm, but should be rounded up or down to be recorded to 
the precision of a single digit after the decimal (i.e., to the nearest 0.1 mm).  The convention for rounding 
decimal values is to round down those ending in 1 to 4 and to round up those ending in 5 to 9. For 
example, a melanoma measuring 0.75 mm in thickness would be recorded as 0.8 mm in thickness (i.e., 
T1b).  Tumors measuring 0.95 mm through 1.04 mm would be rounded to 1.0 mm (i.e., T1b).  Primary 
tumor thickness should be measured using an ocular micrometer that has been calibrated to the 
magnification of the microscope used for the measurement.  Microsatellites should not be included in the 
measurement of tumor thickness. Additional specific recommendations for the measurement of tumor 
thickness in particular clinical circumstances will behave been previously documented33 and will be 
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further detailed in a planned separate publication on pathological aspects of melanoma staging from the 
International Melanoma Pathology Study Group. 
 In the Eighth Edition, the T-category thresholds of melanoma thickness continue to be defined at 
1, 2, and 4 mm (Table 2).3636  However, the T categories have been revised to promote consistency, with 
the recommendation that thickness be rounded to the nearest 0.1 mm, as described above.  Using these 
rounding conventions, T2 melanomas include patients with melanomas with a tumor thickness of 1.05 
mm to 2.04 mm; T2 is now presented as >1.0–2.0 mm, compared to 1.01–2.0 mm in the Seventh 
Edition.37, 38   
Several legacypreviously published reports have indicated that survival among patients with T1 
melanomas is related to tumor thickness, with a possible clinically important “breakpoint” in the region of 
0.7 mm-0.8 mm,.39-42  These observations were explored in the IMDDP database by seeking to identify a 
subgroup of patients with exceptionally good outcome compared to even the most favorable subcategory 
(T1a) in the Seventh Edition,25 and hence in whom SLN biopsy would generally not be indicated.  In the 
T1 cohort, the impact on outcome of a 0.8 mm tumor thickness threshold was evaluated, as well as 
mitotic rate (as a dichotomous variable, <1 mitosis per mm2 vs. ≥1 mitosis per mm2) and ulceration.  In a 
multivariable analysis of factors predicting MSS (including tumor thickness, ulceration, and mitotic rate) 
among 7,568 T1 N0 patients, tumor thickness ≥0.8 mm had a hazard ratio (HR) of 1.7 vs. <0.8 mm (p = 
0.057), ulceration had a HR of 2.6 vs. non-ulcerated (p = 0.035), and mitotic rate ≥1/mm2 had a HR of 
0.85 vs. mitotic rate <1/mm2 (p = 0.57).  Based on these analyses of patients with T1 melanomas, tumor 
thickness (when dichotomized as <0.8 mm and 0.8-1.0 mm) and ulceration were stronger predictors of 
MSS than mitotic rate.  Accordingly, since mitotic rate was not statistically significant in the model, T1 
subcategory definitions have been revised:  T1a is now defined as nonulcerated melanomas <0.8 mm in 
thickness and T1b as melanomas 0.8-1.0 mm in thickness regardless of ulceration status, plus ulcerated 
melanomas <0.8 mm in thickness (Table 2).  The Eighth Edition Melanoma Expert Panel also noted that 
the sub-categorization of T1 melanomas at a 0.8 mm threshold has clinical relevance, particularly for the 
role of SLN biopsy in patients with T1 melanomas.  Overall, SLN metastases are very infrequent (<5%) 
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in melanomas <0.8 mm but occur in approximately 5%-12% of patients with primary melanomas 0.8-1.0 
mm,43-46 and consensus guidelines have recommended that SLN biopsy be considered in this latter 
group of patients, particularly when other adverse prognostic parameters are also present.47-49 
 As in the Seventh Edition, patients with primary melanoma and no evidence of regional or distant 
metastasis are stratified into eight T subcategories (T1a through T4b).  MSS stratified by T subcategory 
for 23,001 patients with complete covariate data is shown in Figure 1.  For these survival curves, 
patients with T1 melanomas were included if they had clinical or pathological T1 N0 melanomas, but 
patients with T2-T4 melanomas were included only if pN0 (i.e., no tumor-containing SLNs and no 
evidence of microsatellites, satellites, or in-transit metastases at diagnosis or following initial treatment).  
Five Overall, this approach aligns with the AJCC Principles of Cancer Staging (see chapter 1 of the 
Eighth Edition AJCC Cancer Staging Manual).56  An implication of this approach is that patients with T2-
T4 melanomas who do not undergo SLN biopsy cannot be pathologically staged.  Nonetheless, the 
Melanoma Expert Panel acknowledges that not all patients with T2-T4 undergo SLN biopsy and 
improved clinical prognostic models and tools (e.g., clinical calculators, etc.) may be developed to 
improve prognostic assessment among this cohort of patients in the future. 
In the Eighth Edition, five- and ten-year MSS ranged from 99% and 98%, respectively, for patients 
with T1a N0 melanomas (i.e., primary tumor thickness <0.8 mm, non-ulcerated), to 82% and 75%, 
respectively, for patients with T4b N0 melanomas (i.e., primary tumor thickness >4.0 mm, ulcerated). 
MSS for all T subcategories were notably higher than those reported in the Seventh Edition, in which 10-
year MSS was 93% and 39% for T1a N0 and T4b N0 melanomas, respectively.50  The higher survival of 
patients in the more contemporary patient cohort examined in this Eighth Edition effort is likely a 
consequence of the widespread use of sentinel nodeSLN biopsy, the requirement for SLN biopsy for 
patients with T2-T4 primary melanoma to be included in AJCC staging, and, to a lesser extent, newer 
imaging technologies that improve detection of clinically occult metastatic disease, thereby defining more 
homogenous groups of patients and achieving more accurate staging.36 3836 38  Some patients, who in the 
past would have been classified as clinically node negative (cN0), would be expected to harbor clinically 
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occult nodal metastasis identified on the basis of a positive SLN biopsy and are classified as pN1, pN2, 
etc., according to the overall number of tumor-involved lymph nodes.  In one study, for example, the risk 
of harboring a positive SLN ranged from 11% in patients with T1a melanoma to 53% in patients with T4b 
melanoma.51  Overall, the presence of an ulcerated primary was generally associated with a MSS 
approximately similar to that of a patient with a nonulcerated primary tumor in the next highest tumor 
thickness category.  These T-category thresholds also inform substaging in patients both without and 
with regional disease in the Eighth Edition staging system (see N stage groups below). 
Other T category definitions have been clarified in the Eighth Edition.  Patients with melanoma in 
situ are properly categorized as Tis (not T0, which is reserved for an unknown or completely regressed 
primary site).  Since tumor thickness can only be evaluated accurately in histological sections cut 
perpendicular to the epidermal surface, the T category should be recorded as TX if the thickness cannot 
be assessed (e.g., in curettage specimens when no tissue fragment shows a complete section of the 
tumor cut perpendicular to the surface).  In some instances, if the tissue has been misembedded, melting 
the paraffin block and re-embedding the tissue may enable perpendicular sections to be obtained.  If 
there is evidence of regression of part of an invasive melanoma, the thickness should be measured in 
the usual way to the deepest identifiable viable tumor cell, and the tumor should be assigned to the 
appropriate T category.  Partially regressed melanoma should not be designated TX or T0.  T0 should be 
used if there is no evidence of a primary tumor (e.g., in a patient who presents with nodal or visceral 
metastasis and no known primary tumor), or if a melanoma has regressed completely.  If the invasive 
component of the melanoma has regressed but overlying in situ melanoma remains, the tumor should be 
designated Tis. 
 
Ulceration 
Primary tumor ulceration is another T category criterion.  In the Eighth Edition, as in the Seventh 
Edition,3838 the absence or presence of ulceration is designated “a” or “b”, respectively, in each T 
subcategory (e.g., T2a and T2b correspond to non-ulcerated and ulcerated T2 melanomas, 
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respectively)(Table 2).  Ulceration is defined as the full thickness absence of an intact epidermis above 
any portion of the primary tumor with associated host reaction (characterized by a fibrinous and acute 
inflammatory exudate) above the primary tumor, based on histopathological examination.  If there is no 
host reaction, this likely represents artefactual loss of an intact epidermis overlying the primary 
melanoma and the melanoma should not be recorded as ulcerated, since this may have resulted from 
sectioning artifact caused by the tissue sectioning techniques used in the laboratory.  Epidermal loss 
caused by a prior biopsy should not be recorded as ulceration for staging purposes.  If ulceration is 
present in either an initial partial biopsy or a re-excision specimen of a primary melanoma, then the tumor 
should be recorded as ulcerated for staging purposes.  While the presence of “squared off” edges of a 
scar can provide a clue to the presence of iatrogenic (prior biopsy related) ulceration, at times it may be 
difficult or impossible to distinguish between iatrogenic and non-iatrogenic causes of ulceration on the 
basis of histopathologic assessment alone, and correlation with the clinical history is essential.5152  If 
doubt remains as to whether ulceration is traumatic or iatrogenic in origin, the tumor should be staged as 
an ulcerated primary tumor. 
Ulceration is an adverse prognostic factor;25, 36, 37, 41, 5253 the presence of an ulcerated primary was 
generally associated with a MSS similar to that of a patient with a nonulcerated primary in the next 
highest tumor thickness category (Figure 1).  For example, the 5- and 10-year MSS for patients with T2b 
pN0 and T3a pN0 primary cutaneous melanomas are 93% and 88%, and 94% and 88%, respectively. 
 
Mitotic rate 
Mitotic rate, defined as the number of mitoses per square millimeter in the invasive portion of the 
tumor using the “hot spot” method,3,363,36 (i.e., count beginning in a region where mitoses are more 
frequent and continue in immediately adjacent non-overlapping high power fields), was a T1 category 
criterion in the Seventh Edition;37,38 it was included as a dichotomous variable defined as <1/mm2 versus 
≥1/mm2.  In the Eighth Edition, mitotic rate was not included as a T1 staging criterion (based on the T1 
analysis described in the tumor thickness section above).  Nevertheless, among patients with clinically 
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node negative (cN0) primary melanoma in the Eighth Edition AJCC melanoma database, increasing 
mitotic rate was significantly associated with decreasing MSS in univariate analysis (Figure 2).  For 
example, in a univariate analysis of MSS for patients with T1-4 pN0 melanoma according to mitotic rate 
(mitoses/mm2) when presentedcategorized as a categorical variable,<1, 1-3, 3-10, >10, the 5- and 10-
year MSS ranged from 99% and 97% in patients whose primary tumor had <1 mitosis/mm2 to 84% and 
77% in patients whose primary tumors had ≥11 mitoses/mm2, respectively. (p < 0.0001, log rank test).  
As supported by this univariate analysis and previous reports,53, 54, 55 mitotic rate is likely an important 
prognostic determinant when evaluated using its dynamic range across melanomas of all tumor 
thickness categories.  Therefore, the AJCC Melanoma Expert Panel strongly recommends that mitotic 
rate be assessed and recorded for all primary melanomas,3, 36 even though it is not used for T1 staging in 
the Eighth Edition.  Mitotic rate will likely be an important parameter for inclusion in the future 
development of prognostic models applicable to individual patients.  While not included in the T1 
subcategory criteria, mitotic activity in T1 melanomas has been previously shown to be associated with 
increased risk of sentinel lymph node metastasis.43, 46, 56, 57 
 
The N category 
The N category documents metastatic disease both in regional lymph nodes and in non-nodal 
loco-regional sites (i.e., microsatellites, satellites and in-transit metastases).  For the Eighth Edition, the 
Melanoma Expert Panel sought to add further granularity throughout the N category by providing clarity 
of definitions. 
Regional Lymph Node Metastasis  
In the Eighth Edition, N category criteria continue to include both extent of regional node tumor 
involvement and number of tumor-involved regional nodes.  “Clinically occult” nodal metastasis describes 
patients with microscopically identified regional node metastasis detected by SLN biopsy and without 
clinical or radiographic evidence of regional node metastasis (termed “microscopic” nodal metastasis in 
the Seventh Edition).  In contrast, “clinically detected” nodal metastasis describes patients with regional 
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node metastasis identifi d by clinical, radiographic or ultrasound examination (termed “macroscopic” 
nodal metastasis in the Seventh Edition) and usually (but not necessarily) confirmed by biopsy.5558  
Clinically occult (N1a, N2a, N3a) and clinically detected (N1b, N2b, N3b) N subcategories define 
patients with regional node disease based on extent of regional node involvement and number of tumor-
involved regional nodes among patients without satellites, microsatellites, or in-transit metastases (Table 
3).  If at least one node is clinically detected, and there are additional involved nodes detected only on 
microscopic examination, the total number of involved nodes (i.e., both those clinically detected and 
those identified only on microscopic examination of a complete lymphadenectomy specimen) should be 
recorded for N subcategory based on the total number of tumor-involved regional nodes.  If 
microsatellites, satellites or in-transit metastases are present, patients are assigned to an N “c” 
subcategory according to the number of tumor-involved regional nodes, regardless of whether clinically 
occult or clinically detected:  N1c, N2c or N3c if 0, 1 or ≥2 regional nodes contain tumor, respectively 
(Table 3). 
As noted in the Seventh Edition, there is no unequivocal evidence that there is a lower threshold 
for the size of a clinically occult melanoma regional node tumor deposit that defines node-positive 
disease for staging purposes.  Thus, a lymph node in which any metastatic tumor cells have been 
identified, irrespective of how small the tumor deposit or whether it has been identified on H&E-stained or 
immunostained sections, should be designated as a tumor-involved lymph node.  In the Eighth Edition, it 
has been clarified that if melanoma cells are found in a lymphatic channel within or immediately adjacent 
to a lymph node, that node is regarded as tumor-involved for staging purposes. 
 In the Eighth Edition, the term “gross extranodal extension” is no longer used as an N category 
criterion, but the presence of matted nodes (defined as two or more nodes adherent to one another 
through involvement by metastatic disease, identified at the time the specimen is examined 
macroscopically in the pathology laboratory) is retained as an N3 criterion.  Even though it is not formally 
included as an Eighth Edition N category criterion, the definition of extranodal extension (ENE, also 
termed extranodal spread or extracapsular extension) has been clarified.  In the Eighth Edition, ENE is 
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defined as the presence of a nodal metastasis extending through the lymph node capsule and into 
adjacent tissue, which may be apparent macroscopically but must be confirmed microscopically.  It is 
recommended that this covariatefactor be recorded, as it may be useful for future analyses.5659 
Patients with clinically occult regional node disease have been shown in several large series to 
have better survival than patients with clinically evident disease.50, 57, 5860, 61  This was also evident in the 
AJCC MSS curves according to N category and N subcategory, shown in Figure 3.  Overall, consistent 
with our observations in the Seventh Edition,25, 37, 5962 there is marked heterogeneity in prognosis among 
patients with Stage III regional node disease by N-category designation.  
Non-nodal Locoregional Metastases (Microsatellite, Satellite and In-transit Metastases) 
The presence or absence of microsatellite, satellite or in-transit metastases, regardless of the 
number of such lesions, are components of the N category in the Eighth Edition (Table 3).  They are all 
thought to represent metastases that are a consequence of intralymphatic or possibly angiotropic tumor 
spread.  Satellite metastases have classically and somewhat arbitrarily been defined as grossly visible or 
palpableclinically evident cutaneous and/or subcutaneous metastases occurring within 2 cm of the 
primary melanoma.50, 6063  Microsatellites have classically been defined as microscopic cutaneous and/or 
subcutaneous metastases found adjacent or deep to a primary melanoma on pathological examination 
(see discussion below).  In-transit metastases have classically and somewhat arbitrarily been defined as 
clinically evident dermalcutaneous and/or subcutaneous metastases identified at a distance more than 2 
cm from the primary melanoma in the region between the primary and the first echelon of regional lymph 
nodes.6063  Beginning with the Sixth Edition AJCC melanoma staging system, satellite and in-transit 
metastases were merged into a single staging entity reflective of intralymphatic regional metastases.6063  
Occasionally, satellite or in-transit metastases may occur distal to the primary site.  An N “c” subcategory 
has been added into each of the N1, N2 and N3 categories (i.e. N1c, N2c, N3c)(Table 3) in the Eighth 
Edition to incorporate contemporary knowledge of the prognostic importance of non-nodal locoregional 
metastases, and to simplify the application of staging rules for patients with them.  Microsatellites, 
satellites and in-transit metastases have been shown to portend a relatively poor prognosis.61-6764-70  In 
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univariate analysis of th  Eighth Edition database that included patients with or without synchronous 
regional node involvement, there was no significant difference in survival outcome for these anatomically 
defined entities (Figure 4); hence, they were grouped together for staging purposes (Table 3).  Planned 
IMDDP multivariable analyses will further explore the prognostic impact of non-nodal regional disease on 
MSS. 
In the Seventh Edition, a microsatellite was defined as “any tumor nest >0.05 mm in diameter that 
was separated by normal dermis from the main invasive component of a melanoma by distance of >0.5 
mm”.  The definition of microsatellite has been clarified and refined, so that in the Eighth Edition, there is 
no minimum size threshold or distance from the primary tumor that defines a microsatellite; it is simply 
defined as a microscopic cutaneous and/or subcutaneous metastasis adjacent to or deep to and 
completely discontinuous from a primary melanoma with unaffected stroma occupying the space 
between, identified on pathological examination of the primary tumor site.  Fibrous scarring and/or 
inflammation noted between an apparently separate nodule and the primary tumor (rather than normal 
stroma) may represent regression of the intervening tumor; if these findings are present, the nodule is 
considered to be an extension of the primary tumor and not a microsatellite.  Although occasionally seen 
in the primary melanoma diagnostic biopsy specimen, microsatellites, when present, are more commonly 
identified in the wide excision specimen. 
Metastatic melanoma in lymph nodes without a known primary tumor  
Patients presenting with melanoma in one or more lymph nodes without a known primary tumor 
were not included in the International Melanoma Database constructed for the analyses informing the 
Eighth Edition.  However, based on data from the published literature (including from patients diagnosed 
before 199868-7071-73) and analysis of patients presenting to Melanoma Institute Australia since 1998,7073 
such patients had an equivalent or slightly better survival than patients with a known primary tumor who 
presented with a similar number of clinically-detected tumor-involved nodes.  The AJCC Melanoma 
Expert Panel recommended that such patients be assigned to the corresponding N category based on 
the number of lymph nodes containing metastatic disease and the presence or absence of satellite, 
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microsatellite or in-transit metastases.  Until additional data are available, melanoma patients with an 
unknown primary with N1b disease should be staged as IIIB whereas all other N categories should be 
staged as IIIC. 
  
The M category 
For the Eighth Edition, the Melanoma Expert Panel concluded that because of the rapidly 
changing and still evolving landscape for the management of patients with Stage IV melanoma, it was 
premature to embark on a broad-based analytic initiative based on new data from patients treated in 
recent years.  Instead, the legacy Seventh Edition AJCC Stage IV international melanoma database was 
used for the Eighth Edition as the primary data source (and no new analyses were conducted), 
supplemented by published contemporary clinical trial data.6-21  In the Eighth Edition, M category 
definitions were clarified and refined and a new category for patients with central nervous system (CNS) 
metastases was added (M1d).  For patients with distant metastases, M1 is defined by both anatomic site 
of distant metastatic disease and serum lactate dehydrogenase level (LDH) for all anatomic site 
subcategories.  
Anatomic site(s) of distant metastatic disease  
The anatomic site(s) of metastasis is used to assign patients to one of four (previously three) M 
subcategories:  M1a, M1b, M1c and, new to the Eighth Edition, M1d (Table 4).  The definition of each M1 
anatomic site subcategory was also clarified.  Patients with distant metastasis to skin, subcutaneous 
tissue, muscle or distant lymph nodes, regardless of serum LDH level, are categorized as M1a.  Patients 
with metastasis to lung (with or without concurrent metastasis to skin, subcutaneous tissue, muscle or 
distant lymph nodes and regardless of serum LDH level) are categorized as M1b.  Patients with 
metastases to any other visceral site(s) (exclusive of the CNS) are designated as M1c.  New to the 
Eighth Edition, patients with metastases to the CNS (i.e., involving the brain, spinal cord, leptomeninges, 
or other components of the CNS)36New to the Eighth Edition, patients with metastases to the CNS (i.e., 
involving the brain, spinal cord, leptomeninges, or other components of the CNS)36 are designated as 
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M1d (irrespective of the presence of metastatic disease at other sites); these patients were previously 
designated as M1c in the Seventh Edition.  This revision to include an M1d category reflects the expert 
panel’s assessment that, in addition to the historically poor overall survival outcome for patients with 
CNS metastases, contemporary clinical trial eligibility and exclusion criteria, as well as stratification and 
analysis, are often based on the presence/absence of CNS disease.6-21, 76, 7774, 75  This additional level of 
granularity in the M category therefore better “maps” to contemporary clinical practice and clinical trial 
decision-making and analysis. 
Serum LDH level  
In the Seventh Edition, an elevated LDH was used to categorize a patient as M1c, regardless of 
anatomic site(s) of metastatic disease, given its significance as an independent adverse predictor of 
survival among patients with Stage IV disease.  LDH remains a clinically significant factor associated 
with response, progression-free survival, MSS and overall survival in the contemporary treatment era of 
targeted and immune therapies.76-78-80  In the Eighth Edition, an elevated LDH level no longer 
independently defines M1c disease.  Instead, in order to better codify the impact of anatomic site and 
LDH level, descriptors were added to the M1 subcategory designation to indicate LDH status (designated 
as “(0)” for not elevated and “(1)” for elevated) for each M1 subcategory (Table 4).   
 
The Stage Groups 
As in prior editions of the AJCC Cancer Staging Manual, both clinical and pathological 
classifications are employed in melanoma staging.  In the Eighth Edition, clinical staging includes 
microstaging of the primary melanoma – as a standard practice, after resection of the primary melanoma 
– and clinical/radiologic assessment for regional and distant metastases, as well as biopsies performed 
to assess for regional and distant metastases as appropriate (Table 5).  There are no substages for 
clinical Stage III melanoma.  Pathological staging includes all clinical staging information, as well as any 
additional staging information derived from the wide excision (surgical) specimen that constitutes primary 
tumor surgical treatment, and pathological information about the clinically node-negative regional lymph 
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nodes after SLN biopsy, with or without completion lymph node dissection (CLND), or therapeutic lymph 
node dissection for clinically evident regional lymph node disease (Table 6).  In patients who undergo 
SLN biopsy and have a clinically occult regional lymph node metastasis identified by SLN biopsy, but 
additional surgery in the form of a CLND is not performed, according to the Eighth Edition Principles of 
Cancer Staging (Chapter 1 of the Eighth Edition AJCC Cancer Staging Manual55) and the Eighth Edition 
melanoma chapter36, category pN1a(sn) is assigned to specify that CLND was not performed.  If a CLND 
is performed, such patients would be assigned to categorysubcategory pN1a (or another pN>0 
subcategory depending on the total number of tumor-involved lymph nodes), to distinguish these two 
clinical scenarios and to improve granularity in coding for clinical and analytic purposes.36, 5558 
Due in part to the low overall likelihood of nodal metastasis and lack of uniformly accepted criteria 
for SLN biopsy in T1 melanoma, neither pathological Stage 0 (melanoma in situ, Tis) nor T1 melanoma 
requires SLN biopsy to complete pathological staging among patients with clinically node-negative 
melanomas.  Instead, cN information is used to assign the pathological stage for T1 melanomas if SLN 
biopsy is not performed.  
The MSS for all patients stratified by pathological stage groups I to III is shown in Figure 5.  
Patients with Stages I, II, and III disease had 5- and 10-year MSS of 98% and 95%, 90% and 84%, and 
77% and 69%, respectively, and were overall slightly improved compared to patients who had similar 
stages of melanoma in the Seventh Edition analyses.25, 37  
 
Stages I and II subgroupings 
For pathological T category stage groups, 5- and 10-year MSS ranged from 99% and 98% in 
patients with Stage IA melanoma, respectively, to 82% and 75% in patients with Stage IIC disease 
(Figure 6).  As in the Seventh Edition, patients with clinical T1b N0 melanoma are included in clinical 
Stage IB.  In contrast, patients with pathological T1b N0 melanoma are included in pathological Stage IA 
(and not IB as in the Seventh Edition) (Table 6).  This stage grouping reflects the better survival of T1b 
patients with pathologically negative nodes, since if SLN biopsy was performed it only includes those 
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with a tumor-negative SLN (i.e., T1b pN1 patients would be Stage III), compared with a group of T1b 
patients who were only clinically staged.  Five- and 10-year MSS were 97% and 93%, respectively, for 
patients with clinical T1b N0 melanoma, compared to 99% and 96% 5- and 10-year MSS, respectively, 
for patients with pathological T1b N0 melanoma. 
Stage III subgroupings 
In the Seventh Edition, both regional node factors (number of nodes involved, microscopic versus 
macroscopic node involvement) as well as primary tumor ulceration, determined Stage III groups.  
Although N category alone predicts MSS in the Eighth Edition analysis (Figure 3), the Melanoma Expert 
Panel hypothesized that more accurate prognostic estimates could be obtained by including both T 
category factors, tumor thickness and ulceration status, along with the number of tumor-involved lymph 
nodes and whether they were detected clinically or were clinically occult (i.e., positive SLN), and the 
presence of microsatellite, satellite, and/or in-transit metastases (i.e., 9 N categories; Table 3).  This was 
evaluated using recursive partitioning analysis.  Initially, 8 pathological Stage III subgroups were created, 
including three “pairs” of subgroups that had similar 5-year MSS (data not shown).  Based on 
discussions by the Melanoma Expert Panel that explored the relative merits of “grouping” versus 
“splitting”, and the observation that adoption of five N stage groups would result in a total of 11 overall 
stage groups across T, N, and M (5+5+1=11) which would not conform to the total number of stage 
groups across the broad AJCC cancer disease site landscape, the 8 subgroups were combined to create 
four Stage III subgroups that maintained the overall prognostic heterogeneity of the base model (Figure 
7).  As such, these four subgroups stratify patients with Stage III melanoma in the Eighth Edition, 
compared to the three subgroups that were used to stratify Stage III patients in the Seventh Edition.25, 37  
A clinic workstation guide to combining T and N categories into Stage III subgroups is provided in Figure 
8 (see also Supplementary Figure 1 for a black and white version).  Five-year MSS according to Stage 
III subgroups ranges from 93% in Stage IIIA patients (1-3 clinically occult tumor-involved SLNs [N1a or 
N2a] and T1a, T1b or T2a primaries) to 32% for Stage IIID patients (patients with a thick and ulcerated 
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primary [T4b] and either four or more tumor-involved regional nodes [N3a or N3b] or two or more tumor-
involved nodes and evidence of microsatellite, satellite or in-transit metastases [N3c]). ]) (Figure 7).  In 
the Seventh Edition, 5-year MSS for Stages IIIA, IIIB, and IIIC disease were 78%, 59% and 40%, 
respectively.37  These differences, particularly for patients with Stage IIIA disease, have implications for 
clinical decision-making and counseling, as well as the design, eligibility, stratification, and analysis of 
adjuvant therapy clinical trials. 
Distant Metastases (Stage IV) 
Although revisions to the M category have been implemented in the Eighth Edition, as described 
in detail above (Tables 4, 5 and 6), no M stage subgroups were proposed and no new data have thus far 
been analyzed.  This is because the availability of contemporary data is limited and because survival 
differences among patients with Stage IV melanoma historically were small (before the recent revolution 
in treatment options for patients with advanced melanoma).  It is anticipated that, as recently-introduced 
systemic therapies gain a foothold in the treatment repertoire of patients with advanced disease and 
even better treatment modalities become available, Stage IV survival outcomes will continue to improve.  
An international Stage IV melanoma database is planned in the future to explore this new and evolving 
treatment landscape for patients with advanced disease. 
 
ADDITIONAL RECOMMENDATIONS  
Multiple primary melanomas – It is well established that patients may be diagnosed with 
synchronous or metachronous primary melanomas.  In general, according to the Eighth Edition AJCC 
Principles of Cancer Staging,55In general, according to the Eighth Edition AJCC Principles of Cancer 
Staging,58 when patients present with multiple primary cutaneous melanomas, each is considered a 
different primary site and each is categorized separately.  In the uncommon clinical scenario where 
patients who harbor regional node metastases have multiple primary melanomas draining to the same 
regional node basin, the primary tumor with the highest T category should be assigned as the 
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originating primary tumor with respect to the nodal metastases; if distant metastases are present, the 
primary tumor with the highest N category (or the highest T category if N0) should be assigned as the 
origin of the distant metastases.5558  Moreover, in patients with multiple primary melanomas, the 
recorded stage should map to the highest stage group of any of the primary tumors.  According to the 
Principles of Cancer Staging,5558 if there are multiple synchronous melanomas with no evidence of 
metastatic disease, the assigned category is based on the tumor with the highest T category, and by 
convention, the m suffix is used.  For example, T2a(m) would be used to describe a 1.4 mm, non-
ulcerated melanoma diagnosed synchronously with a 0.7 mm, non-ulcerated melanoma.  Alternatively, 
another acceptable approach is to designate the number of primary tumors instead of the m suffix (i.e., 
T2a(2) in the above example).5558  To the extent possible, if the number of synchronous multiple primary 
melanomas at presentation is known, this latter approach is preferred by the Melanoma Expert Panel. 
Other important primary tumor factors – Although detailed discussion is beyond the scope of 
this article, in addition to the variables discussed (e.g., tumor thickness, ulceration, mitotic rate), the 
Melanoma Expert Panel recommends routine collection of multiple other known or putative primary tumor 
factors:  level of invasion, tumor-infiltrating lymphocytes, lymphovascular invasion, and neurotropism.  
The interested reader is referred to a comprehensive description and discussion of these and other 
factors in the melanoma chapter of the Eighth Edition AJCC Cancer Staging Manual.3636 
SLN microscopic tumor burden – There is significant and growing evidence that microscopic 
tumor burden in the sentinel node is prognostically important.81-9379-91  Sentinel node tumor burden can be 
assessed by a variety of micromorphometric parameters including the maximum size of the largest 
metastasis, maximum subcapsular depth (also known as tumor penetrative depth89 of the deposits and 
measured from the inner surface of the lymph node capsule to the deepest intranodal tumor cell), the 
microanatomic location of sentinel node tumor deposits, the percentage cross-sectional area of the 
sentinel node that is involved and the presence of extranodal extension.  In various studies, one or more 
of these parameters has predicted survival in SLN positive patients.81-9379-91  
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The impact of extent of SLN tumor burden (based on largest maximum dimension of the largest 
discrete metastatic melanoma deposit) was assessed for the subset of patients with known SLN tumor 
burden in the IMDDP.  In univariate analysis, increasing SLN tumor burden was associated with reduced 
MSS (Figure 9).  Although this histopathological parameter is not a formal staging criterion for the N 
category in the Eighth Edition, documentation of SLN tumor burden is an important prognostic factor that 
will be included in and likely guide the development of future prognostic models and the development of 
ultimately validated clinical tools (e.g., calculators, nomograms, etc.) for patients with regional metastatic 
disease.   
Microscopic SLN tumor burden has already been implemented as an inclusion criterion in some 
clinical trials (e.g., EORTC 18071 - adjuvant ipilimumab in stage III23, 24 and EORTC1325 - adjuvant 
pembrolizumab in stage III24).  In these trials, patients with a single positive SLN must have a 
microscopic tumor burden >1mm in diameter, based on the relatively worse prognosis of this patient 
subgroup.  
Based on the currently available evidence, the AJCC Melanoma Expert Panel recommends that, 
as a minimum, the single largest maximum dimension (measured in millimeters to the nearest 0.1 mm 
using an ocular micrometer) of the largest discrete metastatic melanoma deposit in sentinel nodes be 
recorded in pathology reports.3636  To further advance this field, the AJCC Melanoma Expert Panel and 
International Melanoma Pathology Study Group plan to continue efforts to harmonize and standardize 
assessment and reporting of SLN tumor burden.  Planned IMDDP analyses will also further explore the 
prognostic impact of SLN tumor burden. 
Number of distant metastatic sites and extent of distant metastatic disease burden – The 
number of metastases at distant sites has previously been documented as an important prognostic 
factor. 71, 72, 74, 75, 7977, 92-95  This was also confirmed in previous preliminary multivariable analyses using 
the Seventh Edition AJCC stage IV melanoma database.  However, this feature was not incorporated 
into the Eighth Edition as a formal staging criterion due in part to significant variability in the deployment 
of diagnostic imaging to comprehensively search for distant metastases (ranging from a chest x-ray in 
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some centers to high-resolution double-contrast CT, PET/CT, and MRI in others) as well as the 
heterogeneity with which extent of disease results are codified across databases.  Until recording of the 
indications for and types of investigations used and extent of distant metastatic disease are better 
standardized, the Melanoma Expert Panel concluded that number of metastases cannot reproducibly be 
used for staging purposes.   
Approach to staging patients following neoadjuvant (“up front”) therapy – Historically, 
surgery represented the mainstay of treatment for patients with cutaneous melanoma.  For several solid 
tumors, neoadjuvant therapy (systemic therapy prior to surgical resection) is often used as part of 
multidisciplinary treatment approaches for patients with locally advanced and/or regional disease, and for 
others an “up front” approach using systemic therapy (without a definitive plan for surgery to follow) is 
employed.9496  The availability of effective systemic therapies has greatly expanded potential treatment 
approaches for patients with unresectable and regionally advanced melanoma over the past several 
years and has led to tremendous interest in leveraging these clinical advances to develop neoadjuvant 
strategies for melanoma patients with locally advanced or metastatic disease.  To stage such patients 
after treatment, the Eighth Edition Principles of Cancer Staging includes a posttherapy or post 
neoadjuvant therapy classification – yTNM -- that includes T, N, and M categorization after systemic or 
radiation treatment intended as definitive therapy (ycTNM), or after neoadjuvant therapy followed by 
planned surgery (ypTNM).5558  Although this has been an infrequently utilized classification in melanoma 
to date, given that a robust portfolio of neoadjuvant clinical trials in melanoma patients are currently 
under way, and still more are planned, the “y” classification schema may prove useful in characterizing 
such patients, and the information can be compared to clinical stages assigned to patients before the 
start of neoadjuvant therapy.  Future analyses will likely allow refinement of this not yet widely used 
classification schema.  
Approach to staging patients following recurrence/retreatment – By definition, clinical and 
pathological classification according to the AJCC staging system occurs at initial melanoma presentation.  
Thus, those who have regional node or non-nodal regional metastases at the time of initial presentation 
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are characterized as having Stage III disease, and those who present with distant metastases at the time 
of initial presentation are characterized as having Stage IV disease.  To accommodate staging for 
patients who have recurred, the Eighth Edition Principles of Cancer Staging also includes an additional 
classification schema for patients who recur – rTNM – that is further divided into “r-clinical” (rcTNM) and 
“r-pathological” (rpTNM) stages.  Such an approach may be useful to better characterize extent of 
disease along an individual melanoma patient’s disease continuum.5558  As this staging classification is to 
date relatively unknown and infrequently used by the global melanoma community, future analyses will 
likely inform revisions of this classification schema for patients with recurrent melanoma. 
 
CONCLUSIONS 
In the Eighth Edition AJCC Staging System for cutaneous melanoma, particular attention was 
directed to clarifying major themes and terminology, introducing clinically relevant revisions and creating 
a new, contemporary international database.  The Melanoma Expert Panel focused most of its attention 
on evidence-based revisions of Stages I to III melanoma for the Eighth Edition AJCC Cancer Staging 
Manual, and established a framework for the development of robust and iteratively refined clinical 
prognostic models that will assist in the development of clinical tools to ultimately enhance clinical 
decision making.  Importantly, based on analyses of this contemporary melanoma database, survival 
outcomes for equivalent stage groupings were substantially higher than for similar stage groups of 
patients in prior Editions, including the Seventh Edition, with implications for clinical decision-making and 
clinical trial design, eligibility, stratification, and analysis. 
 Given the rapidly evolving landscape of treatment of Stage IV melanoma in recent years, which 
already has resulted in significantly improved progression-free and overall survival for patients, the 
Melanoma Expert Panel strategically paused and did not establish a Stage IV database or perform 
analyses of Stage IV patients.  Instead new, clinically relevant M category criteria were introduced into 
the Eighth Edition that will facilitate refined collection of Stage IV data including more precise data 
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collection for patients with CNS metastases.  These new criteria will be essential to support future 
assessment of prognosis, as well as clinical trial design, eligibility, stratification, and analysis, for patients 
with advanced melanoma.  Strategic development of analytic efforts for the Stage IV melanoma 
population in the current new era of effective targeted therapies and immunotherapy is now under way as 
part of the IMDDP.  These analyses are expected not only to improve prognostic assessment for patients 
with advanced disease but also to inform further revisions of the staging system, and facilitate the 
development of clinical tools in the foreseeable future. 
 Additional enhancements to the Eighth Edition melanoma staging system, including yTNM and 
rTNM classifications, will enable contemporary melanoma patients to be accurately risk stratified across 
the disease continuum.  This will assist clinicians and patients in clinical management planning and 
enhance the design, conduct and analysis of clinical trials that should ultimately lead to improved patient 
outcomes.  Undoubtedly, melanoma staging will continue to evolve as new prognostic factors and 
evidence-based approaches – including integration of clinical, pathological, molecular and immunological 
endpoints – are developed, refined, and validated.  
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Tables 
Table 1. A summary of the major changes introduced and highlights of the Eighth Edition of the 
AJCC Melanoma Staging System.  
Change Details of Change/Highlight 
Definition of Primary Tumor 
(T) 
All principal T category tumor thickness ranges maintained, but T1 now 
subcategorized by tumor thickness strata at 0.8mm threshold 
Definition of Primary Tumor 
(T) 
Tumor mitotic rate removed as a staging criterion for T1 tumors 
• T1a melanomas now defined as non-ulcerated and less than 
0.8mm in thickness;  
• T1b now defined as melanomas 0.8mm to 1.0mm in thickness 
regardless of ulceration status OR ulcerated melanomas less 
than 0.8mm in thickness 
Definition of Primary Tumor 
(T) 
T0 definition has been clarified – T0 should be used to designate when 
there is no evidence of a primary tumor, or the site of the primary tumor 
is unknown (e.g., in a patient who presents axillary metastasis with no 
known primary tumor); staging may be based on the clinical suspicion of 
the primary tumor with the tumor categorized as T0 (Tis, not T0, 
designates melanoma in situ) 
Definition of Primary Tumor 
(T) 
Tumor thickness measurements now recorded to the nearest 0.1mm, not 
the nearest 0.01mm, because of impracticality and imprecision of 
measurements particularly for tumors >1mm thick. Tumors ≤1mm may 
be measured to the nearest 0.01mm when practical, but should be 
reported rounded to the nearest 0.1mm (e.g., melanomas measured to 
be anywhere in the range from 0.75mm to 0.84mm are reported as 
0.8mm in thickness (and hence T1b) 
Definition of Primary Tumor 
(T) 
Tis (melanoma in situ), T0 (no evidence of or unknown primary tumor), 
and TX (tumor thickness cannot be determined) may now be used as the 
T category designation for stage groupings 
Definition of Regional Lymph 
Node (N) 
Number of metastasis-containing regional lymph nodes maintained 
Definition of Regional Lymph 
Node (N) 
Previously empirically defined “microscopic” and “macroscopic” 
descriptors redefined as “clinically occult” (i.e., clinical Stage I-II with 
nodal metastasis determined at sentinel node biopsy) and “clinically 
apparent” regional node disease (clinical Stage III), respectively 
Definition of Regional Lymph 
Node (N) 
Sentinel node tumor burden is considered a regional disease prognostic 
factor that should be collected for all patents with positive sentinel 
nodes, but is not used to determine N category groupings  
Definition of Regional Lymph 
Node (N) 
Non-nodal regional disease, including microsatellites, satellites, and in-
transit cutaneous and/or subcutaneous metastases more formally 
stratified by N category according to # of tumor involved lymph nodes 
(Presence of microsatellites, satellites, or in-transit metastases now 
categorized as N1c, N2c, or N3c based on number of synchronous 
tumor-involved regional lymph nodes, if any) 
Definition of Regional Lymph 
Node (N) 
“Gross” extranodal extension no longer used as an N staging criterion 
(but the presence of “matted nodes” is retained) 
Definition of Distant 
Metastasis (M) 
M1 now defined by both anatomic site of distant metastatic disease and 
serum lactate dehydrogenase (LDH) value for all anatomic site 
subcategories 
Definition of Distant 
Metastasis (M) 
Descriptions of distant anatomic sites of disease clarified in M 
subcategories 
Formatted Table
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Change Details of Change/Highlight 
Definition of Distant 
Metastasis (M) 
Descriptors now added to M1 subcategory designation that provides 
LDH values (designated as “0” for “not elevated” and “1” for “elevated” 
level) for all sites of distant disease; e.g., skin/soft tissue/nodal 
metastasis with elevated LDH now M1a(1), not M1c 
Definition of Distant 
Metastasis (M) 
New M1d designation added to include distant metastasis to central 
nervous system (CNS), with or without any other distant sites of disease; 
M1c no longer includes CNS metastasis 
Definition of Distant 
Metastasis (M) 
Elevated LDH level no longer defines M1c 
AJCC Prognostic Stage 
Groups 
No overall change in T subcategories, but definition of T1a and T1b 
refined 
AJCC Prognostic Stage 
Groups 
N category now composed of five substages rather than three, and 
Stage III subgroupings are based on multivariable models including T 
category elements (tumor thickness and ulceration) and N category 
elements (# of nodes, satellites/in-transits/microsatellites) demonstrating 
significant impact of primary tumor factors in assigning N substage  
AJCC Prognostic Stage 
Groups 
Clarified that stage IV not further substaged (i.e., M1c is stage IV, not 
stage IVC) 
 
*Used with permission of the American Joint Committee on Cancer (AJCC), Chicago, Illinois. The original 
and primary source for this information is the AJCC Cancer Staging Manual, Eighth Edition (2017) 
published by Springer International Publishing. 
 
Gershenwald, J.E., Scolyer, R.A., et al. Melanoma of the Skin. In: Amin, M.B., Edge, S.B., Greene, F.L., 
et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017: 563-585 
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Table 2. Definition of Primary Tumor (T)  
T Category Thickness Ulceration status 
TX: primary tumor thickness 
cannot be assessed (e.g., 
diagnosis by curettage) 
 
Not applicable  Not applicable 
T0: no evidence of primary tumor 
(e.g., unknown primary or 
completely regressed 
melanoma) 
 
Not applicable 
Not applicable 
Tis (melanoma in situ) Not applicable Not applicable 
T1 ≤1.0 mm Unknown or unspecified 
     T1a <0.8 mm Without ulceration  
     T1b 
<0.8 mm 
0.8–1.0 mm 
With ulceration  
With or without ulceration 
T2 >1.0–2.0 mm Unknown or unspecified 
     T2a >1.0–2.0 mm Without ulceration  
     T2b >1.0–2.0 mm With ulceration 
T3 >2.0-4.0 mm Unknown or unspecified 
     T3a >2.0–4.0 mm Without ulceration 
     T3b >2.0–4.0 mm With ulceration 
T4 >4.0 mm Unknown or unspecified 
     T4a >4.0 mm Without ulceration 
     T4b >4.0 mm With ulceration 
 
*Adapted with permission of the American Joint Committee on Cancer (AJCC), Chicago, Illinois. The 
original and primary source for this information is the AJCC Cancer Staging Manual, Eighth Edition 
(2017) published by Springer International Publishing. 
 
Modified from Gershenwald, J.E., Scolyer, R.A., et al. Melanoma of the Skin. In: Amin, M.B., Edge, S.B., 
Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017: 563-585 
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Table 3. Definition of Regional Lymph Node (N) 
 
Extent of regional lymph node and/or  
lymphatic metastasis 
N Category Number of tumor-involved regional lymph node 
Presence of in-
transit, satellite, 
and/or microsatellite 
metastases 
NX Regional nodes not assessed (e.g., SLN biopsy not performed, 
regional nodes previously removed for another reason)  
Exception: pathological N category is not required for T1 
melanomas, use cN. 
   No 
N0 No regional metastases detected     No 
N1 One tumor-involved node or any number of 
in-transit, satellite, and/or microsatellite 
metastases with no tumor-involved nodes 
 
     N1a  One clinically occult (i.e., detected by SLN biopsy)    No 
     N1b  One clinically detected    No 
     N1c  No regional lymph node disease    Yes 
N2 Two or three tumor-involved nodes or any 
number of in-transit, satellite, and/or 
microsatellite metastases with one tumor-
involved node  
 
     N2a  Two or three clinically occult (i.e., detected by SLN biopsy)     No 
     N2b  Two or three, at least one of which was clinically detected     No 
     N2c One clinically occult or clinically detected    Yes 
N3 Four or more tumor-involved nodes or any 
number of in-transit, satellite, and/or 
microsatellite metastases with two or more 
tumor-involved nodes, or any number of 
matted nodes without or with in-transit, 
satellite, and/or microsatellite metastases   
 
     N3a  Four or more clinically occult (i.e., detected by SLN biopsy)     No 
     N3b Four or more, at least one of which was clinically detected, or 
presence of any number of matted nodes 
   No 
     N3c Two or more clinically occult or clinically detected and/or 
presence of any number of matted nodes 
   Yes 
 
*Adapted with permission of the American Joint Committee on Cancer (AJCC), Chicago, Illinois. The 
original and primary source for this information is the AJCC Cancer Staging Manual, Eighth Edition 
(2017) published by Springer International Publishing. 
 
Modified from Gershenwald, J.E., Scolyer, R.A., et al. Melanoma of the Skin. In: Amin, M.B., Edge, S.B., 
Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017: 563-585 
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Table 4. Definition of Distant Metastasis (M)  
    M Criteria   
M Category Anatomic site LDH level 
M0 No evidence of distant 
metastasis 
Not applicable 
M1 Evidence of distant metastasis See below 
     M1a  Distant metastasis to skin, soft 
tissue including muscle, and/or 
nonregional lymph node  
Not recorded or 
unspecified 
 M1a(0) Not elevated 
 M1a(1) Elevated 
     M1b Distant metastasis to lung with or 
without M1a sites of disease  
Not recorded or 
unspecified 
 M1b(0) Not elevated 
 M1b(1) Elevated 
     M1c  Distant metastasis to non-CNS 
visceral sites with or without M1a 
or M1b sites of disease  
Not recorded or 
unspecified 
 M1c(0) Not elevated 
 M1c(1) Elevated 
     M1d  Distant metastasis to CNS with 
or without M1a, M1b, or M1c 
sites of disease 
Not recorded or 
unspecified 
 M1d(0) Normal 
 M1d(1) Elevated 
Suffixes for M category: (0) LDH not elevated, (1) LDH elevated. 
No suffix is used if LDH is not recorded or is unspecified.  
 
*Used with permission of the American Joint Committee on Cancer (AJCC), Chicago, Illinois. The original 
and primary source for this information is the AJCC Cancer Staging Manual, Eighth Edition (2017) 
published by Springer International Publishing. 
 
Gershenwald, J.E., Scolyer, R.A., et al. Melanoma of the Skin. In: Amin, M.B., Edge, S.B., Greene, F.L., 
et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017: 563-585 
 
Formatted Table
Page 92 of 115CA: A Cancer Journal for Clinicians
This article is protected by copyright. All rights reserved.
A
cc
ep
te
d 
A
rt
ic
le
 
 35
Table 5. AJCC Clinical Prognostic Stage Groups (cTNM) 
When T is& And N is& And M is& Then the clinical 
stage group is& 
Tis N0 M0 0 
T1a N0 M0 IA 
T1b N0 M0 IB 
T2a N0 M0 IB 
T2b N0 M0 IIA 
T3a N0 M0 IIA 
T3b N0 M0 IIB 
T4a N0 M0 IIB 
T4b  N0 M0 IIC 
Any T, Tis ≥N1  M0 III 
Any T Any N M1 IV 
 
*Used with permission of the American Joint Committee on Cancer (AJCC), Chicago, Illinois. The original 
and primary source for this information is the AJCC Cancer Staging Manual, Eighth Edition (2017) 
published by Springer International Publishing. 
 
Gershenwald, J.E., Scolyer, R.A., et al. Melanoma of the Skin. In: Amin, M.B., Edge, S.B., Greene, F.L., 
et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017: 563-585 
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Table 6. AJCC Pathological (pTNM) Prognostic Stage Groups 
 
When T is& And N is& And M is& Then the 
pathological stage 
group is& 
Tis N0 M0 0 
T1a N0 M0 IA 
T1b N0 M0 IA 
T2a N0 M0 IB 
T2b N0 M0 IIA 
T3a N0 M0 IIA 
T3b N0 M0 IIB 
T4a N0 M0 IIB 
T4b N0 M0 IIC 
T0 N1b, N1c M0 IIIB 
T0 N2b, N2c, N3b or N3c M0 IIIC 
T1a/b–T2a N1a or N2a M0 IIIA 
T1a/b–T2a N1b/c or N2b M0 IIIB 
T2b/T3a N1a–N2b M0 IIIB 
T1a–T3a N2c or N3a/b/c M0 IIIC 
T3b/T4a Any N ≥N1 M0 IIIC 
T4b N1a–N2c M0 IIIC 
T4b N3a/b/c M0 IIID 
Any T, Tis Any N M1 IV 
Pathological Stage 0 (melanoma in situ) and T1 do not require pathological evaluation of lymph nodes to 
complete pathological staging; use cN information to assign their pathological stage. 
 
*Used with permission of the American Joint Committee on Cancer (AJCC), Chicago, Illinois. The original 
and primary source for this information is the AJCC Cancer Staging Manual, Eighth Edition (2017) 
published by Springer International Publishing. 
 
Gershenwald, J.E., Scolyer, R.A., et al. Melanoma of the Skin. In: Amin, M.B., Edge, S.B., Greene, F.L., 
et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017: 563-585 
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Supplementary Table 1. Details of the International Melanoma Database and Discovery Platform 
(IMDDP) – Contributors to Current Analysis 
 
 
  
 Location 
 
Institution 
 
Continent 
 
City, State, Country 
No. of Patients 
Contributed to Wave I 
IMDDP Analysis 
 
Melanoma Institute Australia 
 
 
Australia 
 
Sydney, New South 
Wales, Australia 
 
17,276 
 
Melbourne Melanoma 
Project 
 
 
Australia Melbourne, Victoria, 
Australia 
1,408  
Department of Dermatology, 
National and Kapodistrian 
University of Athens School 
of Medicine, Andreas Sygros 
Hospital 
 
Europe 
 
Athens, Greece 
 
468 
 
 
Fondazione IRCCS Istituto 
Nazionale dei Tumori 
 
Europe 
 
Milan, Italy 
 
6,537 
 
 
Instituto Valenciano de 
Oncologia 
Europe 
 
Valencia, Spain 1,392 
 
 
National and Kapodistrian 
University of Athens School 
of Medicine  - General 
Hospital of Athens – Laiko 
 
Europe 
 
Athens, Greece 
 
1,205  
Veneto Institute of 
Oncology-IOV 
 
 
Europe 
 
Padova, Italy 
 
2,954  
John Wayne Cancer Institute 
 
North America Santa Monica, California, 
USA 
6,228  
The University of Texas MD 
Anderson Cancer Center 
North America Houston, Texas, USA 8,023  
 
Winship Cancer Institute of 
Emory University 
North America Atlanta, Georgia, USA 1,495  
Total   46,986  
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Supplementary Table 2 - International Melanoma Database and Discovery Platform  
Data Dictionary. Data elements used for analyses that informed the Eighth Edition (Stages I-III) 
 
Variable Description Acceptable Values 
Patient Demographics   
Collaborator_Patient_ID 
Unique patient identifier for the home institution 
database (de-identified) 
Home institution 
format 
DOB Patient date of birth Date 
Patient_Sex Patient sex 
Male 
Female 
Other/Unknown 
Last_Vital_Date Date of last follow-up Date 
Last_Vital_Status Status at last follow-up  
Alive                                                                                                                        
Deceased 
Cause_Death Cause of death  
Melanoma                                                         
Other                                                                                          
Not applicable 
   
T Category    
KnownPrimary_DX_Staging_Date Date of diagnosis of primary Date 
Primary_Site Anatomic site of primary 
Home institution 
format 
Breslow_Thickness_MM Breslow thickness (mm)* of  primary Numeric 
Ulceration Ulceration status of primary 
Absent                                                                
Present                                                         
Unknown 
Mitoses_PerMM2 Mitoses/mm2  Numeric 
   
N Category   
SLNB_Status Sentinel-lymph node status  
Negative                                                              
Positive                                                               
Not conducted 
Clinical_Detection 
If regional nodes are involved, was there clinical 
detection of regional lymph nodes  
No = detected by SLN biopsy                                                                            
Yes                                            
No  
Unknown
Overall_Positive_Nodes Total number of tumor-involved lymph nodes** Numeric 
Largest_Metastatic_MM 
Largest diameter of the largest metastatic deposit 
in the tumor-involved sentinel node(s) (mm)* 
Numeric 
Tumor_Nodal_Location 
Location(s) of the metastatic deposit(s) in the 
sentinel node 
Subcapsular                                         
Intraparenchymal                                                                          
Both                                                                                              
Unknown 
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Variable Description Acceptable Values 
Extranodal_Extension 
Presence of extranodal extension** of regional 
node(s) at diagnosis 
Absent                                                                
Present                                                         
Unknown 
Microsatellites 
Presence of microsatellites in the primary tumor 
specimen (yes/no) at diagnosis 
Absent                                                                
Present                               
Unknown 
Intransit 
Presence of in-transit and/or satellite lesions at 
diagnosis 
Absent                                                                
Present                                                         
Unknown 
*At the level of precision used by your institution and data team.  
**Including cumulative results from histopathological assessment of staging lymph node procedures, for 
example sentinel node biopsy and completion lymph node dissection OR lymph node biopsy and 
therapeutic lymph node dissection. 
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Figure Legends 
Figure 1.  Kaplan–Meier MSS curves according to T subcategory for patients with Stage I to II 
melanoma from the Eighth Edition international melanoma database. N0 patients have been filtered so 
that T2 to T4 patients were included only if SLN negative, whereas patients with T1N0 melanoma are 
included regardless of whether SLN biopsy was performed.  
 
Figure 2.  Kaplan–Meier MSS curves according to mitotic rate (mitoses per square millimeter) in patients 
with Stage I to II melanoma from the Eighth Edition international melanoma database. N0 patients have 
been filtered so that T2 to T4 patients were included only if SLN negative, whereas patients with T1N0 
melanoma were included regardless of whether SLN biopsy was performed. 
  
Figure 3.  Kaplan–Meier MSS curves according to N categories (A) and subcategories (B) from the 
Eighth Edition international melanoma database  
 
Figure 4.  Kaplan–Meier MSS curves according to the presence or absence of microsatellites, satellites, 
and/or in-transit metastases from the Eighth Edition international melanoma database. (Note: Intransit in 
figure means in-transit and/or satellite metastasis; both means microsatellites and/or in-transit and/or 
satellite metastasis.) 
 
Figure 5.  Kaplan–Meier MSS curves according to Stage in patients with Stage I to III melanoma from 
the Eighth Edition international melanoma database. 
 
Figure 6.  Kaplan–Meier MSS curves according to T category stage group for patients with Stage I to II 
melanoma from the Eighth Edition international melanoma database. N0 patients were filtered so that 
Comment [TG18]: Please check consistency 
of font sizes and styles in figures. There seems 
to be some inconsistency but I can’t be certain 
whether this reflects the original figures or the 
way they were joined in the pdf. 
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T2+ patients are included only if SLN negative, whereas patients with T1N0 melanoma are included 
regardless of whether SLN biopsy was performed.  
 
Figure 7.  Kaplan–Meier MSS curves according to Stage III subgroups from the Eighth Edition 
international melanoma database. 
 
Figure 8.  AJCC Eighth Edition Stage III subgroups based on T and N categories. 
 
 
Figure 9.  Kaplan–Meier MSS curves according to maximum dimension of sentinel node metastatic 
focus (millimeters) from the Eighth Edition international melanoma database. (Note – insufficient data 
exists to estimate 10-year MSS for patients with 2 mm to 4 mm maximum sentinel node metastatic 
focus). 
 
Supplementary Figure 1.  AJCC Eighth Edition Stage III subgroups based on T and N categories (black 
and white version)..). 
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Figure legends included in manuscript file 
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Figure 3 
 
A- N categories - 3 curves 
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 Figure 4 
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Figure 5 
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Figure 6 
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Figure 7 
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Figure 8 
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(1) Select patient’s N category at left of chart.          
(2) Select patient’s T category at top of chart.                               
(3) Note letter at the intersection of T&N on grid.                                                                          
(4) Determine patient's AJCC stage using legend.                               
N/A=Not assigned, please see manual for details. REF
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Category
T Category
Stage IIID
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Supplementary Figure 1 
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